title,date,subpage_url,Therapy class,Product Name,INN,Initial Approval,Cancer,Marketing authorisation holder,CHMP Opinion Date,Decision date,Therapy Area,Orphan,Recommendation
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,D11,Anzupgo,delgocitinib,Initial approval,No,LEO Pharma A/S,25/07/2024,nan,Dermatology,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,A05,Iqirvo,elafibranor,Initial approval,No,Ipsen Pharma,25/07/2024,nan,Alimentary,Yes,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,A05,Kayfanda,odevixibat,Initial approval,No,Ipsen Pharma,25/07/2024,nan,Alimentary,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Loqtorzi,toripalimab,Initial approval,Yes,TMC Pharma (EU) Limited,25/07/2024,nan,Cancer,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,S01,Vevizye,ciclosporin,Initial approval,No,Novaliq GmbH,25/07/2024,nan,Sense organs,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Vyloy,zolbetuximab,Initial approval,Yes,Astellas Pharma Europe B.V.,25/07/2024,nan,Cancer,Yes,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,C02,Yuvanci,macitentan / tadalafil,Initial approval,No,Janssen-Cilag International NV,25/07/2024,nan,Cardiovascular,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,J07,Arexvy,"Respiratory syncytial virus, glycoprotein F, recombinant, stabilised in the pre-fusion conformation, adjuvanted with AS01E",Extension,No,GlaxoSmithkline Biologicals S.A.,nan,27/06/2024,Infectives,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Braftovi,encorafenib,Extension,Yes,Pierre Fabre Medicament,26/07/2018,19/03/2024,Cancer,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,J05,Edurant,rilpivirine,Extension,No,Janssen-Cilag International N.V.,nan,28/10/2022,Infectives,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Mektovi,binimetinib,Extension,Yes,Pierre Fabre Medicament,nan,17/06/2024,Cancer,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Keytruda,pembrolizumab,Extension,Yes,Merck Sharp & Dohme B.V.,20/05/2015,08/07/2024,Cancer,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,C02,Opsumit,macitentan,Extension,No,Janssen-Cilag International N.V.,nan,01/12/2022,Cardiovascular,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Padcev,enfortumab vedotin,Extension,Yes,Astellas Pharma Europe B.V.,24/02/2022,29/11/2023,Cancer,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Rybrevant,amivantamab,Extension,Yes,Janssen-Cilag International N.V.,14/10/2021,27/06/2024,Cancer,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,N05,Slenyto,melatonin,Extension,No,RAD Neurim Pharmaceuticals EEC SARL,26/07/2018,16/02/2024,CNS,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L04,Spevigo,spesolimab,Extension,No,Boehringer Ingelheim International GmbH,13/10/2022,nan,Immuo-mod,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Tecentriq,atezolizumab,Extension,Yes,Roche Registration GmbH,19/07/2017,04/07/2024,Cancer,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 24-27 June 2024,28 June 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-24-27-june-2024,L01,Balversa,erdafitinib,Initial approval,Yes,Janssen-Cilag International N.V.,27/06/2024,nan,Cancer,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 24-27 June 2024,28 June 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-24-27-june-2024,C01,Eurneffy,epinephrine,Initial approval,No,Ars Pharmaceuticals Irl Limited,27/06/2024,nan,Cardiovascular,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 24-27 June 2024,28 June 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-24-27-june-2024,J07,mResvia,Single-stranded 5' capped mRNA encoding the Respiratory syncytial virus glycoprotein F stabilized in the prefusion conformation,Initial approval,No,Moderna Biotech Spain S.L.,27/06/2024,nan,Infectives,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 24-27 June 2024,28 June 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-24-27-june-2024,Not,Ordspono,odronextamab,Initial approval,No,Regeneron Ireland Designated Activity Company,27/06/2024,nan,NONE,Yes,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 24-27 June 2024,28 June 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-24-27-june-2024,L04,Piasky,crovalimab,Initial approval,No,Roche Registration GmbH,27/06/2024,nan,Immuo-mod,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 24-27 June 2024,28 June 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-24-27-june-2024,V09,Tauvid,Flortaucipir (18F),Initial approval,No,Eli Lilly Nederland B.V.,27/06/2024,nan,Various,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 24-27 June 2024,28 June 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-24-27-june-2024,C02,Winrevair,sotatercept,Initial approval,No,Merck Sharp & Dohme B.V.,27/06/2024,nan,Cardiovascular,Yes,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 24-27 June 2024,28 June 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-24-27-june-2024,G04,Betmiga,mirabegron,Extension,No,Astellas Pharma Europe B.V.,nan,26/04/2024,GU,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 24-27 June 2024,28 June 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-24-27-june-2024,J06,Beyfortus,nirsevimab,Extension,No,Sanofi Winthrop Industrie,15/09/2022,15/07/2024,Infectives,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 24-27 June 2024,28 June 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-24-27-june-2024,J02,Cresemba,isavuconazole,Extension,No,Basilea Pharmaceutica Deutschland GmbH,23/07/2005,11/04/2024,Infectives,Yes,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 24-27 June 2024,28 June 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-24-27-june-2024,A08,Imcivree,setmelanotide,Extension,No,Rhythm Pharmaceuticals Netherlands B.V.,20/05/2021,14/05/2024,Alimentary,Yes,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 24-27 June 2024,28 June 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-24-27-june-2024,L01,Imfinzi,durvalumab,Extension,Yes,AstraZeneca AB,26/07/2018,26/07/2024,Cancer,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 24-27 June 2024,28 June 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-24-27-june-2024,N/A,Infanrix hexa,"diphtheria, tetanus, pertussis (acellular, component), hepatitis B (rDNA), poliomyelitis (inact.) and haemophilus type B conjugate vaccine (adsorbed)",Extension,N/A,GlaxoSmithkline Biologicals SA,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 24-27 June 2024,28 June 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-24-27-june-2024,L01,Lynparza,olaparib,Extension,Yes,AstraZeneca AB,nan,12/08/2024,Cancer,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 24-27 June 2024,28 June 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-24-27-june-2024,L03,Pegasys,peginterferon alfa-2a,Extension,No,Pharmaand GmbH,21/03/2002,11/10/2023,Immuo-mod,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 24-27 June 2024,28 June 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-24-27-june-2024,L01,Tepkinly,epcoritamab,Extension,Yes,AbbVie Deutschland GmbH & Co. KG,20/07/2023,08/04/2024,Cancer,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 24-27 June 2024,28 June 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-24-27-june-2024,S01,Vabysmo,faricimab,Extension,No,Roche Registration GmbH,21/07/2022,08/02/2024,Sense organs,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 24-27 June 2024,28 June 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-24-27-june-2024,L01,Xalkori,crizotinib,Extension,Yes,Pfizer Europe MA EEIG,19/07/2012,28/10/2022,Cancer,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 27-30 May 2024,31 May 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-27-30-may-2024,B01,Adzynma,rADAMTS13,Initial approval,No,Takeda Manufacturing Austria AG,30/05/2024,01/08/2024,Blood,Yes,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 27-30 May 2024,31 May 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-27-30-may-2024,S01,Akantior,polihexanide,Initial approval,No,SIFI SPA,30/05/2024,nan,Sense organs,Yes,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 27-30 May 2024,31 May 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-27-30-may-2024,L01,Cejemly,sugemalimab,Initial approval,Yes,SFL Pharmaceuticals Deutschland GmbH,30/05/2024,nan,Cancer,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 27-30 May 2024,31 May 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-27-30-may-2024,N/A,Durveqtix,fidanacogene elaparvovec,Initial approval,N/A,Pfizer Europe MA EEIG,30/05/2024,nan,N/A,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 27-30 May 2024,31 May 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-27-30-may-2024,J07,Fluenz,"influenza vaccine (live attenuated, nasal)",Initial approval,No,AstraZeneca AB,21/05/2024,17/07/2024,Infectives,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 27-30 May 2024,31 May 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-27-30-may-2024,V09,GalliaPharm,Germanium (68Ge) chloride / Gallium (68Ga) chloride,Initial approval,No,Eckert & Ziegler Radiopharma GmbH,30/05/2024,01/08/2024,Various,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 27-30 May 2024,31 May 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-27-30-may-2024,N/A,Ixchiq,Chikungunya vaccine (live),Initial approval,N/A,Valneva Austria GmbH,30/05/2024,nan,N/A,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 27-30 May 2024,31 May 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-27-30-may-2024,H04,Zegalogue,dasiglucagon,Initial approval,No,N/A,30/05/2024,nan,N/A,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 27-30 May 2024,31 May 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-27-30-may-2024,D11,Dupixent,dupilumab,Extension,No,Sanofi Winthrop Industrie,20/07/2017,28/06/2024,Dermatology,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 27-30 May 2024,31 May 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-27-30-may-2024,B01,Eliquis,apixaban,Extension,No,Bristol-Myers Squibb / Pfizer EEIG,17/03/2011,26/07/2024,Blood,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 27-30 May 2024,31 May 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-27-30-may-2024,A07,Kinpeygo,budesonide,Extension,No,STADA Arzneimittel AG,19/05/2022,24/07/2024,Alimentary,Yes,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 27-30 May 2024,31 May 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-27-30-may-2024,A05,Livmarli,maralixibat,Extension,No,Mirum Pharmaceuticals International B.V.,13/10/2022,28/06/2024,Alimentary,Yes,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 27-30 May 2024,31 May 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-27-30-may-2024,L04,Skyrizi,risankizumab,Extension,No,AbbVie Deutschland GmbH & Co. KG,28/02/2019,24/07/2024,Immuo-mod,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 27-30 May 2024,31 May 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-27-30-may-2024,L01,Tagrisso,osimertinib,Extension,Yes,AstraZeneca AB,17/12/2015,28/06/2024,Cancer,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 27-30 May 2024,31 May 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-27-30-may-2024,L01,Tevimbra,tislelizumab,Extension,Yes,BeiGene Ireland Ltd,20/07/2023,08/07/2024,Cancer,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 April 2024,7 May 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-april-2024,B02,Altuvoct,efanesoctocog alfa,Initial approval,No,Swedish Orphan Biovitrum AB (publ),25/04/2024,nan,Blood,Yes,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 April 2024,7 May 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-april-2024,L01,Fruzaqla,fruquintinib,Initial approval,Yes,Takeda Pharmaceuticals International AG Ireland Branch,25/04/2024,18/07/2024,Cancer,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 April 2024,7 May 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-april-2024,C02,Jeraygo,aprocitentan,Initial approval,No,Idorsia Pharmaceuticals Deutschland GmbH,26/04/2024,01/08/2024,Cardiovascular,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 April 2024,7 May 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-april-2024,G04,Obgemsa,vibegron,Initial approval,No,Pierre Fabre Medicament,25/04/2024,nan,GU,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 April 2024,7 May 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-april-2024,L01,Truqap,capivasertib,Initial approval,Yes,AstraZeneca AB,25/04/2024,nan,Cancer,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 April 2024,7 May 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-april-2024,L01,Alecensa,alectinib,Extension,Yes,Roche Registration GmbH,15/12/2016,06/06/2024,Cancer,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 April 2024,7 May 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-april-2024,L01,Opdivo,nivolumab,Extension,Yes,Bristol-Myers Squibb Pharma EEIG,23/04/2015,03/07/2024,Cancer,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 April 2024,7 May 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-april-2024,L01,Rozlytrek,entrectinib,Extension,Yes,Roche Registration GmbH,28/05/2020,27/06/2024,Cancer,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 April 2024,7 May 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-april-2024,L01,Rybrevant,amivantamab,Extension,Yes,Janssen-Cilag International N.V.,14/10/2021,27/06/2024,Cancer,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 April 2024,7 May 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-april-2024,J04,Sirturo,bedaquiline,Extension,No,Janssen-Cilag International N.V.,nan,17/06/2024,Infectives,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 April 2024,7 May 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-april-2024,J05,Triumeq,dolutegravir / abacavir / lamivudine,Extension,No,ViiV Healthcare B.V.,26/06/2014,27/05/2024,Infectives,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 18-21 March 2024,22 March 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-18-21-march-2024,A10,Awiqli,insulin icodec,Initial approval,No,Novo Nordisk A/S,21/03/2024,nan,Diabetes,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 18-21 March 2024,22 March 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-18-21-march-2024,J01,Emblaveo,aztreonam / avibactam,Initial approval,No,Pfizer Europe Ma EEIG,21/03/2024,nan,Infectives,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 18-21 March 2024,22 March 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-18-21-march-2024,L04,Fabhalta,iptacopan,Initial approval,No,Novartis Europharm Limited,21/03/2024,17/05/2024,Immuo-mod,Yes,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 18-21 March 2024,22 March 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-18-21-march-2024,S01,Lytenava,bevacizumab,Initial approval,No,Outlook Therapeutics Limited,21/03/2024,nan,Sense organs,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 18-21 March 2024,22 March 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-18-21-march-2024,L04,Bimzelx,bimekizumab,Extension,No,UCB Pharma S.A,24/06/2021,01/08/2024,Immuo-mod,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 18-21 March 2024,22 March 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-18-21-march-2024,C10,Nilemdo,bempedoic acid,Extension,No,Daiichi Sankyo Europe GmbH,30/01/2020,10/05/2024,Cardiovascular,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 18-21 March 2024,22 March 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-18-21-march-2024,C10,Nustendi,bempedoic acid / ezetimibe,Extension,No,Daiichi Sankyo Europe GmbH,30/01/2020,10/05/2024,Cardiovascular,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 18-21 March 2024,22 March 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-18-21-march-2024,N/A,Onivyde pegylated liposomal,irinotecan hydrochloride trihydrate,Extension,N/A,Les Laboratoires Servier,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 18-21 March 2024,22 March 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-18-21-march-2024,L01,Retsevmo,selpercatinib,Extension,Yes,Eli Lilly Nederland B.V.,10/12/2020,11/07/2024,Cancer,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 18-21 March 2024,22 March 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-18-21-march-2024,L02,Xtandi,enzalutamide,Extension,Yes,Astellas Pharma Europe B.V.,25/04/2013,20/06/2024,Cancer,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 19-22 February 2024,23 February 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-19-22-february-2024,J07,Celldemic,"zoonotic influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted, prepared in cell cultures)",Initial approval,No,Seqirus Netherlands B.V.,22/02/2024,nan,Infectives,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 19-22 February 2024,23 February 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-19-22-february-2024,C09,Filspari,sparsentan,Initial approval,No,Vifor France,22/02/2024,26/06/2024,Cardiovascular,Yes,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 19-22 February 2024,23 February 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-19-22-february-2024,J07,Incellipan,"pandemic influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted, prepared in cell cultures)",Initial approval,No,Seqirus Netherlands B.V.,22/02/2024,nan,Infectives,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 19-22 February 2024,23 February 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-19-22-february-2024,N07,Qalsody,tofersen,Initial approval,No,Biogen Netherlands B.V.,22/02/2024,09/07/2024,CNS,Yes,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 19-22 February 2024,23 February 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-19-22-february-2024,L01,Tizveni,tislelizumab,Initial approval,Yes,Beigene Ireland Limited,22/02/2024,nan,Cancer,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 19-22 February 2024,23 February 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-19-22-february-2024,L04,Voydeya,danicopan,Initial approval,No,Alexion Europe,22/02/2024,nan,Immuo-mod,Yes,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 19-22 February 2024,23 February 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-19-22-february-2024,L01,Zynyz,retifanlimab,Initial approval,Yes,Incyte Biosciences Distribution B.V.,22/02/2024,nan,Cancer,Yes,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 19-22 February 2024,23 February 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-19-22-february-2024,L01,Carvykti,ciltacabtagene autoleucel,Extension,Yes,Janssen-Cilag International NV,24/03/2022,26/07/2024,Cancer,Yes,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 19-22 February 2024,23 February 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-19-22-february-2024,D11,Cibinqo,abrocitinib,Extension,No,Pfizer Europe MA EEIG,14/10/2021,20/08/2024,Dermatology,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 19-22 February 2024,23 February 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-19-22-february-2024,R07,Kalydeco,ivacaftor,Extension,No,Vertex Pharmaceuticals (Ireland) Limited,20/11/2023,12/06/2024,Respiratory,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 19-22 February 2024,23 February 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-19-22-february-2024,L01,Keytruda,pembrolizumab,Extension,Yes,Merck Sharp & Dohme B.V.,20/05/2015,08/07/2024,Cancer,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 19-22 February 2024,23 February 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-19-22-february-2024,B03,Reblozyl,luspatercept,Extension,No,Bristol-Myers Squibb Pharma EEIG,30/04/2020,27/03/2024,Blood,Yes,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 19-22 February 2024,23 February 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-19-22-february-2024,L01,Xromi,hydroxycarbamide,Extension,Yes,Nova Laboratories Ireland Limited,nan,16/05/2024,Cancer,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 January 2024,26 January 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-january-2024,J01,Exblifep,cefepime / enmetazobactam,Initial approval,No,Advanz Pharma Limited,25/01/2024,nan,Infectives,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 January 2024,26 January 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-january-2024,L03,Ryzneuta,efbemalenograstim alfa,Initial approval,No,Evive Biotechnology Ireland Limited,25/01/2023,14/05/2024,Immuo-mod,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 January 2024,26 January 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-january-2024,L01,Abecma,idecabtagene vicleucel,Extension,Yes,Bristol-Myers Squibb Pharma EEIG,24/06/2021,20/06/2024,Cancer,Yes,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 January 2024,26 January 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-january-2024,N/A,Prevenar 20 (previously Apexxnar),"pneumococcal polysaccharide conjugate vaccine (20-valent, adsorbed)",Extension,N/A,Pfizer Europe MA EEIG,16/12/2021,11/04/2024,N/A,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 January 2024,26 January 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-january-2024,L04,Aspaveli,pegcetacoplan,Extension,No,Swedish Orphan Biovitrum AB (publ),16/09/2021,16/07/2024,Immuo-mod,Yes,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 January 2024,26 January 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-january-2024,L01,Retsevmo,selpercatinib,Extension,Yes,Eli Lilly Nederland B.V.,10/12/2020,11/07/2024,Cancer,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 11-14 December 2023,15 December 2023,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-11-14-december-2023,B06,Casgevy,exagamglogene autotemcel,Initial approval,No,Vertex Pharmaceuticals (Ireland) Limited,14/12/2023,21/03/2024,Blood,Yes,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 11-14 December 2023,15 December 2023,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-11-14-december-2023,N/A,Skyclarys,omaveloxolone,Initial approval,N/A,Reata Ireland Limited,14/12/2023,03/08/2024,N/A,Yes,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 11-14 December 2023,15 December 2023,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-11-14-december-2023,L04,Velsipity,etrasimod,Initial approval,No,Pfizer Europe MA EEIG,14/12/2023,13/06/2024,Immuo-mod,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 11-14 December 2023,15 December 2023,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-11-14-december-2023,J06,HyQvia,human normal immunoglobulin,Extension,No,Baxalta Innovations GmbH,21/03/2013,16/05/2024,Infectives,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 11-14 December 2023,15 December 2023,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-11-14-december-2023,B01,Metalyse,Tenecteplase,Extension,No,Boehringer Ingelheim International GmbH,nan,12/01/2024,Blood,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 11-14 December 2023,15 December 2023,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-11-14-december-2023,B02,VeraSeal,human fibrinogen / human thrombin,Extension,No,"Instituto Grifols, S.A.",14/09/2017,25/01/2024,Blood,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 11-14 December 2023,15 December 2023,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-11-14-december-2023,J06,Zinplava,bezlotoxumab,Extension,No,Merck Sharp & Dohme B.V.,10/11/2016,26/01/2024,Infectives,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 6-9 November 2023,10 November 2023,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-6-9-november-2023,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 6-9 November 2023,10 November 2023,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-6-9-november-2023,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 6-9 November 2023,10 November 2023,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-6-9-november-2023,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 6-9 November 2023,10 November 2023,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-6-9-november-2023,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 6-9 November 2023,10 November 2023,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-6-9-november-2023,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 6-9 November 2023,10 November 2023,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-6-9-november-2023,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 6-9 November 2023,10 November 2023,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-6-9-november-2023,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 6-9 November 2023,10 November 2023,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-6-9-november-2023,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 6-9 November 2023,10 November 2023,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-6-9-november-2023,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 6-9 November 2023,10 November 2023,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-6-9-november-2023,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 9-12 October 2023,13 October 2023,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-9-12-october-2023,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 9-12 October 2023,13 October 2023,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-9-12-october-2023,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 9-12 October 2023,13 October 2023,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-9-12-october-2023,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 9-12 October 2023,13 October 2023,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-9-12-october-2023,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 9-12 October 2023,13 October 2023,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-9-12-october-2023,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 9-12 October 2023,13 October 2023,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-9-12-october-2023,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 9-12 October 2023,13 October 2023,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-9-12-october-2023,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 9-12 October 2023,13 October 2023,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-9-12-october-2023,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 9-12 October 2023,13 October 2023,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-9-12-october-2023,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 9-12 October 2023,13 October 2023,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-9-12-october-2023,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 9-12 October 2023,13 October 2023,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-9-12-october-2023,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 9-12 October 2023,13 October 2023,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-9-12-october-2023,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 9-12 October 2023,13 October 2023,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-9-12-october-2023,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 11-14 September 2023,15 September 2023,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-11-14-september-2023,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 11-14 September 2023,15 September 2023,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-11-14-september-2023,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 11-14 September 2023,15 September 2023,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-11-14-september-2023,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 11-14 September 2023,15 September 2023,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-11-14-september-2023,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 11-14 September 2023,15 September 2023,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-11-14-september-2023,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 11-14 September 2023,15 September 2023,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-11-14-september-2023,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 11-14 September 2023,15 September 2023,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-11-14-september-2023,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 11-14 September 2023,15 September 2023,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-11-14-september-2023,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 11-14 September 2023,15 September 2023,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-11-14-september-2023,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 11-14 September 2023,15 September 2023,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-11-14-september-2023,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 11-14 September 2023,15 September 2023,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-11-14-september-2023,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 11-14 September 2023,15 September 2023,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-11-14-september-2023,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 11-14 September 2023,15 September 2023,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-11-14-september-2023,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 11-14 September 2023,15 September 2023,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-11-14-september-2023,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 11-14 September 2023,15 September 2023,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-11-14-september-2023,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 17-20 July 2023,21 July 2023,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-17-20-july-2023,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 17-20 July 2023,21 July 2023,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-17-20-july-2023,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 17-20 July 2023,21 July 2023,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-17-20-july-2023,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 17-20 July 2023,21 July 2023,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-17-20-july-2023,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 17-20 July 2023,21 July 2023,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-17-20-july-2023,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 17-20 July 2023,21 July 2023,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-17-20-july-2023,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 17-20 July 2023,21 July 2023,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-17-20-july-2023,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 17-20 July 2023,21 July 2023,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-17-20-july-2023,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 17-20 July 2023,21 July 2023,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-17-20-july-2023,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 17-20 July 2023,21 July 2023,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-17-20-july-2023,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 17-20 July 2023,21 July 2023,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-17-20-july-2023,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 17-20 July 2023,21 July 2023,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-17-20-july-2023,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 17-20 July 2023,21 July 2023,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-17-20-july-2023,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 17-20 July 2023,21 July 2023,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-17-20-july-2023,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 17-20 July 2023,21 July 2023,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-17-20-july-2023,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 19-22 June 2023,23 June 2023,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-19-22-june-2023,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 19-22 June 2023,23 June 2023,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-19-22-june-2023,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 19-22 June 2023,23 June 2023,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-19-22-june-2023,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 19-22 June 2023,23 June 2023,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-19-22-june-2023,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 19-22 June 2023,23 June 2023,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-19-22-june-2023,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 19-22 June 2023,23 June 2023,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-19-22-june-2023,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 19-22 June 2023,23 June 2023,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-19-22-june-2023,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 19-22 June 2023,23 June 2023,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-19-22-june-2023,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 May 2023,26 May 2023,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-may-2023,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 May 2023,26 May 2023,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-may-2023,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 24 - 26 April 2023,26 May 2023,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-24-26-april-2023,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 24 - 26 April 2023,26 May 2023,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-24-26-april-2023,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 24 - 26 April 2023,26 May 2023,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-24-26-april-2023,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 24 - 26 April 2023,26 May 2023,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-24-26-april-2023,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 24 - 26 April 2023,26 May 2023,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-24-26-april-2023,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 24 - 26 April 2023,26 May 2023,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-24-26-april-2023,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 24 - 26 April 2023,26 May 2023,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-24-26-april-2023,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 24 - 26 April 2023,26 May 2023,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-24-26-april-2023,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 24 - 26 April 2023,26 May 2023,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-24-26-april-2023,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 24 - 26 April 2023,26 May 2023,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-24-26-april-2023,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 24 - 26 April 2023,26 May 2023,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-24-26-april-2023,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 24 - 26 April 2023,26 May 2023,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-24-26-april-2023,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 24 - 26 April 2023,26 May 2023,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-24-26-april-2023,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 24 - 26 April 2023,26 May 2023,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-24-26-april-2023,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 27 - 30 March 2023,31 March 2023,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-27-30-march-2023,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 27 - 30 March 2023,31 March 2023,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-27-30-march-2023,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 27 - 30 March 2023,31 March 2023,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-27-30-march-2023,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 27 - 30 March 2023,31 March 2023,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-27-30-march-2023,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 27 - 30 March 2023,31 March 2023,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-27-30-march-2023,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 27 - 30 March 2023,31 March 2023,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-27-30-march-2023,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 27 - 30 March 2023,31 March 2023,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-27-30-march-2023,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 27 - 30 March 2023,31 March 2023,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-27-30-march-2023,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 20 - 23 February 2023,24 February 2023,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-20-23-february-2023,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 20 - 23 February 2023,24 February 2023,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-20-23-february-2023,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 20 - 23 February 2023,24 February 2023,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-20-23-february-2023,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 20 - 23 February 2023,24 February 2023,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-20-23-february-2023,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 20 - 23 February 2023,24 February 2023,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-20-23-february-2023,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 20 - 23 February 2023,24 February 2023,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-20-23-february-2023,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 20 - 23 February 2023,24 February 2023,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-20-23-february-2023,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 20 - 23 February 2023,24 February 2023,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-20-23-february-2023,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 20 - 23 February 2023,24 February 2023,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-20-23-february-2023,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 23-26 January 2023,27 January 2023,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-23-26-january-2023,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 23-26 January 2023,27 January 2023,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-23-26-january-2023,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 23-26 January 2023,27 January 2023,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-23-26-january-2023,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 23-26 January 2023,27 January 2023,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-23-26-january-2023,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 23-26 January 2023,27 January 2023,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-23-26-january-2023,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 23-26 January 2023,27 January 2023,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-23-26-january-2023,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 12-15 December 2022,16 December 2022,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-12-15-december-2022,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 12-15 December 2022,16 December 2022,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-12-15-december-2022,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 12-15 December 2022,16 December 2022,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-12-15-december-2022,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 12-15 December 2022,16 December 2022,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-12-15-december-2022,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 12-15 December 2022,16 December 2022,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-12-15-december-2022,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 12-15 December 2022,16 December 2022,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-12-15-december-2022,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 12-15 December 2022,16 December 2022,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-12-15-december-2022,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 12-15 December 2022,16 December 2022,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-12-15-december-2022,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 12-15 December 2022,16 December 2022,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-12-15-december-2022,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 12-15 December 2022,16 December 2022,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-12-15-december-2022,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 12-15 December 2022,16 December 2022,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-12-15-december-2022,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 7-10 November 2022,11 November 2022,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-7-10-november-2022,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 7-10 November 2022,11 November 2022,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-7-10-november-2022,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 7-10 November 2022,11 November 2022,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-7-10-november-2022,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 7-10 November 2022,11 November 2022,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-7-10-november-2022,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 7-10 November 2022,11 November 2022,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-7-10-november-2022,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 7-10 November 2022,11 November 2022,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-7-10-november-2022,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 7-10 November 2022,11 November 2022,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-7-10-november-2022,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 7-10 November 2022,11 November 2022,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-7-10-november-2022,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 7-10 November 2022,11 November 2022,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-7-10-november-2022,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 7-10 November 2022,11 November 2022,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-7-10-november-2022,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 10-13 October 2022,14 October 2022,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-10-13-october-2022,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 10-13 October 2022,14 October 2022,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-10-13-october-2022,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 10-13 October 2022,14 October 2022,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-10-13-october-2022,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 10-13 October 2022,14 October 2022,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-10-13-october-2022,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 10-13 October 2022,14 October 2022,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-10-13-october-2022,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 10-13 October 2022,14 October 2022,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-10-13-october-2022,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 10-13 October 2022,14 October 2022,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-10-13-october-2022,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 10-13 October 2022,14 October 2022,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-10-13-october-2022,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 10-13 October 2022,14 October 2022,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-10-13-october-2022,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 12-15 September 2022,22 September 2022,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-12-15-september-2022,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 12-15 September 2022,22 September 2022,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-12-15-september-2022,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 12-15 September 2022,22 September 2022,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-12-15-september-2022,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 12-15 September 2022,22 September 2022,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-12-15-september-2022,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 12-15 September 2022,22 September 2022,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-12-15-september-2022,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 12-15 September 2022,22 September 2022,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-12-15-september-2022,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 12-15 September 2022,22 September 2022,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-12-15-september-2022,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 12-15 September 2022,22 September 2022,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-12-15-september-2022,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 12-15 September 2022,22 September 2022,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-12-15-september-2022,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 12-15 September 2022,22 September 2022,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-12-15-september-2022,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 12-15 September 2022,22 September 2022,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-12-15-september-2022,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 12-15 September 2022,22 September 2022,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-12-15-september-2022,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 12-15 September 2022,22 September 2022,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-12-15-september-2022,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 12-15 September 2022,22 September 2022,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-12-15-september-2022,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 12-15 September 2022,22 September 2022,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-12-15-september-2022,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 12-15 September 2022,22 September 2022,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-12-15-september-2022,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 18-21 July 2022,22 July 2022,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-18-21-july-2022,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 18-21 July 2022,22 July 2022,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-18-21-july-2022,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 18-21 July 2022,22 July 2022,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-18-21-july-2022,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 18-21 July 2022,22 July 2022,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-18-21-july-2022,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 18-21 July 2022,22 July 2022,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-18-21-july-2022,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 18-21 July 2022,22 July 2022,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-18-21-july-2022,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 18-21 July 2022,22 July 2022,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-18-21-july-2022,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 18-21 July 2022,22 July 2022,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-18-21-july-2022,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 18-21 July 2022,22 July 2022,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-18-21-july-2022,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 18-21 July 2022,22 July 2022,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-18-21-july-2022,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 18-21 July 2022,22 July 2022,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-18-21-july-2022,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 18-21 July 2022,22 July 2022,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-18-21-july-2022,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 18-21 July 2022,22 July 2022,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-18-21-july-2022,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 18-21 July 2022,22 July 2022,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-18-21-july-2022,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 24-27 January 2022,5 July 2022,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-24-27-january-2022,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 24-27 January 2022,5 July 2022,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-24-27-january-2022,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 24-27 January 2022,5 July 2022,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-24-27-january-2022,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 24-27 January 2022,5 July 2022,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-24-27-january-2022,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 24-27 January 2022,5 July 2022,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-24-27-january-2022,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 24-27 January 2022,5 July 2022,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-24-27-january-2022,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 24-27 January 2022,5 July 2022,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-24-27-january-2022,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 24-27 January 2022,5 July 2022,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-24-27-january-2022,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 20-23 June 2022,24 June 2022,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-20-23-june-2022,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 20-23 June 2022,24 June 2022,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-20-23-june-2022,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 20-23 June 2022,24 June 2022,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-20-23-june-2022,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 20-23 June 2022,24 June 2022,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-20-23-june-2022,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 20-23 June 2022,24 June 2022,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-20-23-june-2022,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 20-23 June 2022,24 June 2022,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-20-23-june-2022,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 20-23 June 2022,24 June 2022,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-20-23-june-2022,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 20-23 June 2022,24 June 2022,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-20-23-june-2022,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 20-23 June 2022,24 June 2022,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-20-23-june-2022,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 20-23 June 2022,24 June 2022,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-20-23-june-2022,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 20-23 June 2022,24 June 2022,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-20-23-june-2022,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 20-23 June 2022,24 June 2022,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-20-23-june-2022,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 20-23 June 2022,24 June 2022,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-20-23-june-2022,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 16-19 May 2022,20 May 2022,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-16-19-may-2022,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 16-19 May 2022,20 May 2022,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-16-19-may-2022,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 16-19 May 2022,20 May 2022,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-16-19-may-2022,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 16-19 May 2022,20 May 2022,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-16-19-may-2022,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 16-19 May 2022,20 May 2022,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-16-19-may-2022,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 16-19 May 2022,20 May 2022,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-16-19-may-2022,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 16-19 May 2022,20 May 2022,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-16-19-may-2022,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 16-19 May 2022,20 May 2022,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-16-19-may-2022,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 19-22 April 2022,22 April 2022,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-19-22-april-2022,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 19-22 April 2022,22 April 2022,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-19-22-april-2022,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 19-22 April 2022,22 April 2022,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-19-22-april-2022,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 19-22 April 2022,22 April 2022,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-19-22-april-2022,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 19-22 April 2022,22 April 2022,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-19-22-april-2022,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 19-22 April 2022,22 April 2022,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-19-22-april-2022,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 19-22 April 2022,22 April 2022,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-19-22-april-2022,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 19-22 April 2022,22 April 2022,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-19-22-april-2022,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 21-24 March 2022,25 March 2022,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-21-24-march-2022,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 21-24 March 2022,25 March 2022,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-21-24-march-2022,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 21-24 March 2022,25 March 2022,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-21-24-march-2022,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 21-24 March 2022,25 March 2022,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-21-24-march-2022,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 21-24 March 2022,25 March 2022,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-21-24-march-2022,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 21-24 February 2022,25 February 2022,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-21-24-february-2022,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 21-24 February 2022,25 February 2022,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-21-24-february-2022,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 21-24 February 2022,25 February 2022,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-21-24-february-2022,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 21-24 February 2022,25 February 2022,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-21-24-february-2022,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 21-24 February 2022,25 February 2022,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-21-24-february-2022,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 21-24 February 2022,25 February 2022,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-21-24-february-2022,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 21-24 February 2022,25 February 2022,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-21-24-february-2022,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 21-24 February 2022,25 February 2022,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-21-24-february-2022,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 21-24 February 2022,25 February 2022,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-21-24-february-2022,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 21-24 February 2022,25 February 2022,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-21-24-february-2022,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 21-24 February 2022,25 February 2022,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-21-24-february-2022,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 13-16 December 2021,17 December 2021,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-13-16-december-2021,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 13-16 December 2021,17 December 2021,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-13-16-december-2021,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 13-16 December 2021,17 December 2021,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-13-16-december-2021,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 13-16 December 2021,17 December 2021,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-13-16-december-2021,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 13-16 December 2021,17 December 2021,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-13-16-december-2021,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 13-16 December 2021,17 December 2021,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-13-16-december-2021,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 13-16 December 2021,17 December 2021,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-13-16-december-2021,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 13-16 December 2021,17 December 2021,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-13-16-december-2021,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 13-16 December 2021,17 December 2021,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-13-16-december-2021,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 13-16 December 2021,17 December 2021,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-13-16-december-2021,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 13-16 December 2021,17 December 2021,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-13-16-december-2021,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 13-16 December 2021,17 December 2021,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-13-16-december-2021,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 13-16 December 2021,17 December 2021,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-13-16-december-2021,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 8-11 November 2021,12 November 2021,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-8-11-november-2021,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 8-11 November 2021,12 November 2021,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-8-11-november-2021,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 8-11 November 2021,12 November 2021,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-8-11-november-2021,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 8-11 November 2021,12 November 2021,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-8-11-november-2021,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 8-11 November 2021,12 November 2021,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-8-11-november-2021,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 8-11 November 2021,12 November 2021,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-8-11-november-2021,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 8-11 November 2021,12 November 2021,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-8-11-november-2021,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 8-11 November 2021,12 November 2021,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-8-11-november-2021,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 8-11 November 2021,12 November 2021,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-8-11-november-2021,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 8-11 November 2021,12 November 2021,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-8-11-november-2021,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 8-11 November 2021,12 November 2021,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-8-11-november-2021,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 8-11 November 2021,12 November 2021,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-8-11-november-2021,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 8-11 November 2021,12 November 2021,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-8-11-november-2021,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 8-11 November 2021,12 November 2021,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-8-11-november-2021,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 11-14 October 2021,15 October 2021,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-11-14-october-2021,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 11-14 October 2021,15 October 2021,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-11-14-october-2021,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 11-14 October 2021,15 October 2021,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-11-14-october-2021,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 11-14 October 2021,15 October 2021,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-11-14-october-2021,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 11-14 October 2021,15 October 2021,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-11-14-october-2021,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 11-14 October 2021,15 October 2021,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-11-14-october-2021,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 11-14 October 2021,15 October 2021,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-11-14-october-2021,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 11-14 October 2021,15 October 2021,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-11-14-october-2021,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 11-14 October 2021,15 October 2021,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-11-14-october-2021,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 11-14 October 2021,15 October 2021,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-11-14-october-2021,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 11-14 October 2021,15 October 2021,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-11-14-october-2021,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 11-14 October 2021,15 October 2021,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-11-14-october-2021,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 11-14 October 2021,15 October 2021,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-11-14-october-2021,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 13-16 September 2021,17 September 2021,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-13-16-september-2021,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 13-16 September 2021,17 September 2021,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-13-16-september-2021,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 13-16 September 2021,17 September 2021,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-13-16-september-2021,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 13-16 September 2021,17 September 2021,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-13-16-september-2021,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 13-16 September 2021,17 September 2021,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-13-16-september-2021,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 13-16 September 2021,17 September 2021,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-13-16-september-2021,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 13-16 September 2021,17 September 2021,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-13-16-september-2021,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 13-16 September 2021,17 September 2021,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-13-16-september-2021,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 13-16 September 2021,17 September 2021,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-13-16-september-2021,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 13-16 September 2021,17 September 2021,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-13-16-september-2021,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 13-16 September 2021,17 September 2021,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-13-16-september-2021,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 13-16 September 2021,17 September 2021,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-13-16-september-2021,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 19-22 July 2021,23 July 2021,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-19-22-july-2021,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 19-22 July 2021,23 July 2021,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-19-22-july-2021,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 19-22 July 2021,23 July 2021,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-19-22-july-2021,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 21-24 June 2021,25 June 2021,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-21-24-june-2021,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 21-24 June 2021,25 June 2021,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-21-24-june-2021,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 21-24 June 2021,25 June 2021,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-21-24-june-2021,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 21-24 June 2021,25 June 2021,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-21-24-june-2021,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 21-24 June 2021,25 June 2021,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-21-24-june-2021,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 21-24 June 2021,25 June 2021,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-21-24-june-2021,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 21-24 June 2021,25 June 2021,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-21-24-june-2021,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 21-24 June 2021,25 June 2021,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-21-24-june-2021,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 21-24 June 2021,25 June 2021,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-21-24-june-2021,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 17-20 May 2021,21 May 2021,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-17-20-may-2021,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 17-20 May 2021,21 May 2021,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-17-20-may-2021,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 17-20 May 2021,21 May 2021,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-17-20-may-2021,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 17-20 May 2021,21 May 2021,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-17-20-may-2021,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 17-20 May 2021,21 May 2021,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-17-20-may-2021,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 17-20 May 2021,21 May 2021,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-17-20-may-2021,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 17-20 May 2021,21 May 2021,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-17-20-may-2021,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 17-20 May 2021,21 May 2021,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-17-20-may-2021,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 17-20 May 2021,21 May 2021,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-17-20-may-2021,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 17-20 May 2021,21 May 2021,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-17-20-may-2021,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 17-20 May 2021,21 May 2021,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-17-20-may-2021,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 17-20 May 2021,21 May 2021,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-17-20-may-2021,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 17-20 May 2021,21 May 2021,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-17-20-may-2021,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 17-20 May 2021,21 May 2021,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-17-20-may-2021,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 17-20 May 2021,21 May 2021,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-17-20-may-2021,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 17-20 May 2021,21 May 2021,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-17-20-may-2021,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 17-20 May 2021,21 May 2021,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-17-20-may-2021,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 17-20 May 2021,21 May 2021,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-17-20-may-2021,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 17-20 May 2021,21 May 2021,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-17-20-may-2021,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 17-20 May 2021,21 May 2021,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-17-20-may-2021,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 19-22 April 2021,23 April 2021,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-19-22-april-2021,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 19-22 April 2021,23 April 2021,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-19-22-april-2021,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 19-22 April 2021,23 April 2021,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-19-22-april-2021,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 19-22 April 2021,23 April 2021,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-19-22-april-2021,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 March 2021,26 March 2021,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-march-2021,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 March 2021,26 March 2021,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-march-2021,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 March 2021,26 March 2021,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-march-2021,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 February 2021,26 February 2021,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-february-2021,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 February 2021,26 February 2021,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-february-2021,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 February 2021,26 February 2021,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-february-2021,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 February 2021,26 February 2021,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-february-2021,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 February 2021,26 February 2021,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-february-2021,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 February 2021,26 February 2021,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-february-2021,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 25-29 January 2021,1 February 2021,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-25-29-january-2021,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 25-29 January 2021,1 February 2021,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-25-29-january-2021,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 25-29 January 2021,1 February 2021,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-25-29-january-2021,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 25-29 January 2021,1 February 2021,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-25-29-january-2021,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 25-29 January 2021,1 February 2021,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-25-29-january-2021,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 25-29 January 2021,1 February 2021,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-25-29-january-2021,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 25-29 January 2021,1 February 2021,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-25-29-january-2021,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 25-29 January 2021,1 February 2021,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-25-29-january-2021,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 25-29 January 2021,1 February 2021,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-25-29-january-2021,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 25-29 January 2021,1 February 2021,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-25-29-january-2021,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 25-29 January 2021,1 February 2021,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-25-29-january-2021,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 7-10 December 2020,11 December 2020,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-7-10-december-2020,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 7-10 December 2020,11 December 2020,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-7-10-december-2020,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 7-10 December 2020,11 December 2020,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-7-10-december-2020,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 7-10 December 2020,11 December 2020,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-7-10-december-2020,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 7-10 December 2020,11 December 2020,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-7-10-december-2020,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 7-10 December 2020,11 December 2020,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-7-10-december-2020,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 7-10 December 2020,11 December 2020,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-7-10-december-2020,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 7-10 December 2020,11 December 2020,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-7-10-december-2020,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 7-10 December 2020,11 December 2020,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-7-10-december-2020,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 7-10 December 2020,11 December 2020,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-7-10-december-2020,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 7-10 December 2020,11 December 2020,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-7-10-december-2020,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 7-10 December 2020,11 December 2020,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-7-10-december-2020,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 7-10 December 2020,11 December 2020,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-7-10-december-2020,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 7-10 December 2020,11 December 2020,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-7-10-december-2020,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 7-10 December 2020,11 December 2020,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-7-10-december-2020,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 9-12 November 2020,13 November 2020,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-9-12-november-2020,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 9-12 November 2020,13 November 2020,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-9-12-november-2020,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 9-12 November 2020,13 November 2020,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-9-12-november-2020,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 9-12 November 2020,13 November 2020,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-9-12-november-2020,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 9-12 November 2020,13 November 2020,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-9-12-november-2020,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 9-12 November 2020,13 November 2020,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-9-12-november-2020,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 9-12 November 2020,13 November 2020,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-9-12-november-2020,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 12-15 October 2020,16 October 2020,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-12-15-october-2020,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 12-15 October 2020,16 October 2020,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-12-15-october-2020,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 12-15 October 2020,16 October 2020,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-12-15-october-2020,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 12-15 October 2020,16 October 2020,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-12-15-october-2020,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 12-15 October 2020,16 October 2020,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-12-15-october-2020,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 12-15 October 2020,16 October 2020,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-12-15-october-2020,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 12-15 October 2020,16 October 2020,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-12-15-october-2020,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 12-15 October 2020,16 October 2020,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-12-15-october-2020,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 12-15 October 2020,16 October 2020,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-12-15-october-2020,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 12-15 October 2020,16 October 2020,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-12-15-october-2020,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 12-15 October 2020,16 October 2020,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-12-15-october-2020,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 12-15 October 2020,16 October 2020,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-12-15-october-2020,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 12-15 October 2020,16 October 2020,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-12-15-october-2020,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 12-15 October 2020,16 October 2020,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-12-15-october-2020,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 12-15 October 2020,16 October 2020,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-12-15-october-2020,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 12-15 October 2020,16 October 2020,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-12-15-october-2020,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 12-15 October 2020,16 October 2020,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-12-15-october-2020,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 14-17 September 2020,18 September 2020,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-14-17-september-2020,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 14-17 September 2020,18 September 2020,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-14-17-september-2020,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 14-17 September 2020,18 September 2020,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-14-17-september-2020,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 14-17 September 2020,18 September 2020,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-14-17-september-2020,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 14-17 September 2020,18 September 2020,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-14-17-september-2020,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 14-17 September 2020,18 September 2020,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-14-17-september-2020,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 14-17 September 2020,18 September 2020,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-14-17-september-2020,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 14-17 September 2020,18 September 2020,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-14-17-september-2020,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 14-17 September 2020,18 September 2020,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-14-17-september-2020,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 14-17 September 2020,18 September 2020,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-14-17-september-2020,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 14-17 September 2020,18 September 2020,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-14-17-september-2020,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 14-17 September 2020,18 September 2020,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-14-17-september-2020,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 14-17 September 2020,18 September 2020,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-14-17-september-2020,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 14-17 September 2020,18 September 2020,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-14-17-september-2020,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 14-17 September 2020,18 September 2020,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-14-17-september-2020,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 14-17 September 2020,18 September 2020,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-14-17-september-2020,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 20-23 July 2020,24 July 2020,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-20-23-july-2020,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 20-23 July 2020,24 July 2020,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-20-23-july-2020,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 20-23 July 2020,24 July 2020,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-20-23-july-2020,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 20-23 July 2020,24 July 2020,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-20-23-july-2020,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 20-23 July 2020,24 July 2020,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-20-23-july-2020,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 20-23 July 2020,24 July 2020,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-20-23-july-2020,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 20-23 July 2020,24 July 2020,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-20-23-july-2020,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 20-23 July 2020,24 July 2020,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-20-23-july-2020,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 20-23 July 2020,24 July 2020,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-20-23-july-2020,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 20-23 July 2020,24 July 2020,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-20-23-july-2020,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 20-23 July 2020,24 July 2020,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-20-23-july-2020,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 20-23 July 2020,24 July 2020,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-20-23-july-2020,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 20-23 July 2020,24 July 2020,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-20-23-july-2020,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 20-23 July 2020,24 July 2020,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-20-23-july-2020,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 June 2020,26 June 2020,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-june-2020,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 June 2020,26 June 2020,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-june-2020,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 June 2020,26 June 2020,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-june-2020,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 June 2020,26 June 2020,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-june-2020,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 June 2020,26 June 2020,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-june-2020,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 June 2020,26 June 2020,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-june-2020,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 25-28 May 2020,29 May 2020,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-25-28-may-2020,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 25-28 May 2020,29 May 2020,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-25-28-may-2020,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 25-28 May 2020,29 May 2020,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-25-28-may-2020,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 25-28 May 2020,29 May 2020,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-25-28-may-2020,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 25-28 May 2020,29 May 2020,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-25-28-may-2020,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 25-28 May 2020,29 May 2020,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-25-28-may-2020,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 25-28 May 2020,29 May 2020,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-25-28-may-2020,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 25-28 May 2020,29 May 2020,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-25-28-may-2020,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 25-28 May 2020,29 May 2020,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-25-28-may-2020,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 28-30 April 2020,30 April 2020,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-28-30-april-2020,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 28-30 April 2020,30 April 2020,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-28-30-april-2020,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 28-30 April 2020,30 April 2020,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-28-30-april-2020,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 28-30 April 2020,30 April 2020,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-28-30-april-2020,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 28-30 April 2020,30 April 2020,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-28-30-april-2020,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 28-30 April 2020,30 April 2020,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-28-30-april-2020,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 28-30 April 2020,30 April 2020,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-28-30-april-2020,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 28-30 April 2020,30 April 2020,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-28-30-april-2020,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 28-30 April 2020,30 April 2020,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-28-30-april-2020,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 28-30 April 2020,30 April 2020,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-28-30-april-2020,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 28-30 April 2020,30 April 2020,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-28-30-april-2020,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 23-26 March 2020 (updated),27 March 2020,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-23-26-march-2020-updated,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 23-26 March 2020 (updated),27 March 2020,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-23-26-march-2020-updated,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 23-26 March 2020 (updated),27 March 2020,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-23-26-march-2020-updated,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 23-26 March 2020 (updated),27 March 2020,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-23-26-march-2020-updated,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 23-26 March 2020 (updated),27 March 2020,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-23-26-march-2020-updated,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 23-26 March 2020 (updated),27 March 2020,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-23-26-march-2020-updated,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 23-26 March 2020 (updated),27 March 2020,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-23-26-march-2020-updated,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 23-26 March 2020 (updated),27 March 2020,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-23-26-march-2020-updated,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 23-26 March 2020 (updated),27 March 2020,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-23-26-march-2020-updated,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 23-26 March 2020 (updated),27 March 2020,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-23-26-march-2020-updated,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 23-26 March 2020 (updated),27 March 2020,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-23-26-march-2020-updated,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 24-27 February 2020,28 February 2020,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-24-27-february-2020,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 24-27 February 2020,28 February 2020,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-24-27-february-2020,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 27-30 January 2020,31 January 2020,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-27-30-january-2020,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 27-30 January 2020,31 January 2020,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-27-30-january-2020,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 27-30 January 2020,31 January 2020,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-27-30-january-2020,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 27-30 January 2020,31 January 2020,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-27-30-january-2020,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 27-30 January 2020,31 January 2020,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-27-30-january-2020,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 27-30 January 2020,31 January 2020,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-27-30-january-2020,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 27-30 January 2020,31 January 2020,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-27-30-january-2020,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 27-30 January 2020,31 January 2020,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-27-30-january-2020,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 27-30 January 2020,31 January 2020,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-27-30-january-2020,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 27-30 January 2020,31 January 2020,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-27-30-january-2020,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 27-30 January 2020,31 January 2020,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-27-30-january-2020,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 27-30 January 2020,31 January 2020,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-27-30-january-2020,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 9-12 December 2019,13 December 2019,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-9-12-december-2019,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 9-12 December 2019,13 December 2019,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-9-12-december-2019,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 9-12 December 2019,13 December 2019,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-9-12-december-2019,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 9-12 December 2019,13 December 2019,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-9-12-december-2019,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 9-12 December 2019,13 December 2019,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-9-12-december-2019,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 9-12 December 2019,13 December 2019,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-9-12-december-2019,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 9-12 December 2019,13 December 2019,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-9-12-december-2019,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 9-12 December 2019,13 December 2019,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-9-12-december-2019,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 9-12 December 2019,13 December 2019,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-9-12-december-2019,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 9-12 December 2019,13 December 2019,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-9-12-december-2019,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 9-12 December 2019,13 December 2019,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-9-12-december-2019,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 9-12 December 2019,13 December 2019,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-9-12-december-2019,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 9-12 December 2019,13 December 2019,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-9-12-december-2019,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 11-14 November 2019 (updated),15 November 2019,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-11-14-november-2019-updated,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 11-14 November 2019 (updated),15 November 2019,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-11-14-november-2019-updated,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 11-14 November 2019 (updated),15 November 2019,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-11-14-november-2019-updated,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 11-14 November 2019 (updated),15 November 2019,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-11-14-november-2019-updated,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 11-14 November 2019 (updated),15 November 2019,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-11-14-november-2019-updated,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 14-17 October 2019,18 October 2019,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-14-17-october-2019,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 14-17 October 2019,18 October 2019,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-14-17-october-2019,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 14-17 October 2019,18 October 2019,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-14-17-october-2019,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 14-17 October 2019,18 October 2019,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-14-17-october-2019,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 14-17 October 2019,18 October 2019,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-14-17-october-2019,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 14-17 October 2019,18 October 2019,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-14-17-october-2019,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 14-17 October 2019,18 October 2019,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-14-17-october-2019,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 16-19 September 2019,20 September 2019,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-16-19-september-2019,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 16-19 September 2019,20 September 2019,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-16-19-september-2019,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 16-19 September 2019,20 September 2019,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-16-19-september-2019,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 16-19 September 2019,20 September 2019,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-16-19-september-2019,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 16-19 September 2019,20 September 2019,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-16-19-september-2019,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 16-19 September 2019,20 September 2019,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-16-19-september-2019,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 16-19 September 2019,20 September 2019,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-16-19-september-2019,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 16-19 September 2019,20 September 2019,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-16-19-september-2019,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 16-19 September 2019,20 September 2019,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-16-19-september-2019,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 16-19 September 2019,20 September 2019,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-16-19-september-2019,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 16-19 September 2019,20 September 2019,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-16-19-september-2019,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 16-19 September 2019,20 September 2019,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-16-19-september-2019,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 16-19 September 2019,20 September 2019,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-16-19-september-2019,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 16-19 September 2019,20 September 2019,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-16-19-september-2019,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2019,26 July 2019,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2019,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2019,26 July 2019,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2019,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2019,26 July 2019,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2019,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2019,26 July 2019,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2019,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2019,26 July 2019,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2019,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2019,26 July 2019,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2019,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2019,26 July 2019,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2019,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2019,26 July 2019,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2019,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2019,26 July 2019,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2019,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2019,26 July 2019,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2019,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 24-27 June 2019,28 June 2019,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-24-27-june-2019,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 24-27 June 2019,28 June 2019,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-24-27-june-2019,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 24-27 June 2019,28 June 2019,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-24-27-june-2019,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 24-27 June 2019,28 June 2019,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-24-27-june-2019,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 24-27 June 2019,28 June 2019,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-24-27-june-2019,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 24-27 June 2019,28 June 2019,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-24-27-june-2019,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 24-27 June 2019,28 June 2019,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-24-27-june-2019,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 24-27 June 2019,28 June 2019,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-24-27-june-2019,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 24-27 June 2019,28 June 2019,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-24-27-june-2019,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 24-27 June 2019,28 June 2019,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-24-27-june-2019,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 24-27 June 2019,28 June 2019,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-24-27-june-2019,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 27-29 May 2019,29 May 2019,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-27-29-may-2019,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 23-26 April 2019,26 April 2019,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-23-26-april-2019,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 23-26 April 2019,26 April 2019,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-23-26-april-2019,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 23-26 April 2019,26 April 2019,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-23-26-april-2019,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 23-26 April 2019,26 April 2019,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-23-26-april-2019,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 23-26 April 2019,26 April 2019,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-23-26-april-2019,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 23-26 April 2019,26 April 2019,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-23-26-april-2019,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 23-26 April 2019,26 April 2019,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-23-26-april-2019,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 23-26 April 2019,26 April 2019,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-23-26-april-2019,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 23-26 April 2019,26 April 2019,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-23-26-april-2019,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 23-26 April 2019,26 April 2019,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-23-26-april-2019,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 23-26 April 2019,26 April 2019,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-23-26-april-2019,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 23-26 April 2019,26 April 2019,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-23-26-april-2019,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 23-26 April 2019,26 April 2019,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-23-26-april-2019,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 23-26 April 2019,26 April 2019,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-23-26-april-2019,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 23-26 April 2019,26 April 2019,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-23-26-april-2019,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 23-26 April 2019,26 April 2019,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-23-26-april-2019,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 25-28 March 2019,29 March 2019,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-25-28-march-2019,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 25-28 March 2019,29 March 2019,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-25-28-march-2019,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 25-28 March 2019,29 March 2019,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-25-28-march-2019,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 25-28 March 2019,29 March 2019,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-25-28-march-2019,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 25-28 March 2019,29 March 2019,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-25-28-march-2019,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 25-28 February 2019,1 March 2019,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-25-28-february-2019,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 25-28 February 2019,1 March 2019,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-25-28-february-2019,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 25-28 February 2019,1 March 2019,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-25-28-february-2019,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 25-28 February 2019,1 March 2019,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-25-28-february-2019,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 25-28 February 2019,1 March 2019,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-25-28-february-2019,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 25-28 February 2019,1 March 2019,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-25-28-february-2019,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 25-28 February 2019,1 March 2019,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-25-28-february-2019,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 25-28 February 2019,1 March 2019,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-25-28-february-2019,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 25-28 February 2019,1 March 2019,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-25-28-february-2019,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 25-28 February 2019,1 March 2019,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-25-28-february-2019,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 25-28 February 2019,1 March 2019,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-25-28-february-2019,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 25-28 February 2019,1 March 2019,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-25-28-february-2019,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 25-28 February 2019,1 March 2019,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-25-28-february-2019,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 25-28 February 2019,1 March 2019,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-25-28-february-2019,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 25-28 February 2019,1 March 2019,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-25-28-february-2019,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 25-28 February 2019,1 March 2019,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-25-28-february-2019,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 25-28 February 2019,1 March 2019,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-25-28-february-2019,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 25-28 February 2019,1 March 2019,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-25-28-february-2019,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 25-28 February 2019,1 March 2019,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-25-28-february-2019,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 25-28 February 2019,1 March 2019,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-25-28-february-2019,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 25-28 February 2019,1 March 2019,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-25-28-february-2019,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 25-28 February 2019,1 March 2019,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-25-28-february-2019,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 28-31 January 2019,1 February 2019,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-28-31-january-2019,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 28-31 January 2019,1 February 2019,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-28-31-january-2019,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 28-31 January 2019,1 February 2019,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-28-31-january-2019,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 28-31 January 2019,1 February 2019,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-28-31-january-2019,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 28-31 January 2019,1 February 2019,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-28-31-january-2019,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 28-31 January 2019,1 February 2019,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-28-31-january-2019,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 28-31 January 2019,1 February 2019,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-28-31-january-2019,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 28-31 January 2019,1 February 2019,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-28-31-january-2019,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 28-31 January 2019,1 February 2019,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-28-31-january-2019,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 28-31 January 2019,1 February 2019,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-28-31-january-2019,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 28-31 January 2019,1 February 2019,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-28-31-january-2019,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 28-31 January 2019,1 February 2019,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-28-31-january-2019,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 28-31 January 2019,1 February 2019,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-28-31-january-2019,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 28-31 January 2019,1 February 2019,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-28-31-january-2019,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 28-31 January 2019,1 February 2019,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-28-31-january-2019,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 28-31 January 2019,1 February 2019,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-28-31-january-2019,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 28-31 January 2019,1 February 2019,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-28-31-january-2019,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 28-31 January 2019,1 February 2019,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-28-31-january-2019,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 28-31 January 2019,1 February 2019,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-28-31-january-2019,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 28-31 January 2019,1 February 2019,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-28-31-january-2019,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 10-13 December 2018,14 December 2018,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-10-13-december-2018,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 10-13 December 2018,14 December 2018,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-10-13-december-2018,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 10-13 December 2018,14 December 2018,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-10-13-december-2018,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 10-13 December 2018,14 December 2018,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-10-13-december-2018,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 10-13 December 2018,14 December 2018,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-10-13-december-2018,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 10-13 December 2018,14 December 2018,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-10-13-december-2018,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 10-13 December 2018,14 December 2018,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-10-13-december-2018,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 10-13 December 2018,14 December 2018,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-10-13-december-2018,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 10-13 December 2018,14 December 2018,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-10-13-december-2018,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 10-13 December 2018,14 December 2018,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-10-13-december-2018,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 10-13 December 2018,14 December 2018,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-10-13-december-2018,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 10-13 December 2018,14 December 2018,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-10-13-december-2018,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 10-13 December 2018,14 December 2018,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-10-13-december-2018,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 10-13 December 2018,14 December 2018,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-10-13-december-2018,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 10-13 December 2018,14 December 2018,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-10-13-december-2018,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 10-13 December 2018,14 December 2018,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-10-13-december-2018,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 10-13 December 2018,14 December 2018,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-10-13-december-2018,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 10-13 December 2018,14 December 2018,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-10-13-december-2018,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 12-15 November 2018,16 November 2018,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-12-15-november-2018,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 12-15 November 2018,16 November 2018,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-12-15-november-2018,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 12-15 November 2018,16 November 2018,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-12-15-november-2018,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 12-15 November 2018,16 November 2018,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-12-15-november-2018,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 12-15 November 2018,16 November 2018,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-12-15-november-2018,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 12-15 November 2018,16 November 2018,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-12-15-november-2018,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 12-15 November 2018,16 November 2018,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-12-15-november-2018,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 12-15 November 2018,16 November 2018,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-12-15-november-2018,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 12-15 November 2018,16 November 2018,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-12-15-november-2018,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 12-15 November 2018,16 November 2018,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-12-15-november-2018,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 12-15 November 2018,16 November 2018,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-12-15-november-2018,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 12-15 November 2018,16 November 2018,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-12-15-november-2018,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 12-15 November 2018,16 November 2018,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-12-15-november-2018,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 12-15 November 2018,16 November 2018,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-12-15-november-2018,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 12-15 November 2018,16 November 2018,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-12-15-november-2018,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 12-15 November 2018,16 November 2018,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-12-15-november-2018,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 12-15 November 2018,16 November 2018,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-12-15-november-2018,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 12-15 November 2018,16 November 2018,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-12-15-november-2018,N/A,N/A,N/A,Extension,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 15-18 October 2018,19 October 2018,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-15-18-october-2018,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 15-18 October 2018,19 October 2018,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-15-18-october-2018,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 15-18 October 2018,19 October 2018,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-15-18-october-2018,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 15-18 October 2018,19 October 2018,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-15-18-october-2018,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 15-18 October 2018,19 October 2018,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-15-18-october-2018,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 15-18 October 2018,19 October 2018,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-15-18-october-2018,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 15-18 October 2018,19 October 2018,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-15-18-october-2018,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 15-18 October 2018,19 October 2018,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-15-18-october-2018,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 15-18 October 2018,19 October 2018,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-15-18-october-2018,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 15-18 October 2018,19 October 2018,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-15-18-october-2018,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 15-18 October 2018,19 October 2018,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-15-18-october-2018,N/A,N/A,N/A,Initial approval,N/A,N/A,N/A,N/A,N/A,N/A,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,D11,Anzupgo,delgocitinib,Initial approval,No,LEO Pharma A/S,25/07/2024,nan,Dermatology,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,A05,Iqirvo,elafibranor,Initial approval,No,Ipsen Pharma,25/07/2024,nan,Alimentary,Yes,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,A05,Kayfanda,odevixibat,Initial approval,No,Ipsen Pharma,25/07/2024,nan,Alimentary,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Loqtorzi,toripalimab,Initial approval,Yes,TMC Pharma (EU) Limited,25/07/2024,nan,Cancer,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,S01,Vevizye,ciclosporin,Initial approval,No,Novaliq GmbH,25/07/2024,nan,Sense organs,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Vyloy,zolbetuximab,Initial approval,Yes,Astellas Pharma Europe B.V.,25/07/2024,nan,Cancer,Yes,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,C02,Yuvanci,macitentan / tadalafil,Initial approval,No,Janssen-Cilag International NV,25/07/2024,nan,Cardiovascular,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,J07,Arexvy,"Respiratory syncytial virus, glycoprotein F, recombinant, stabilised in the pre-fusion conformation, adjuvanted with AS01E",Extension,No,GlaxoSmithkline Biologicals S.A.,nan,27/06/2024,Infectives,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Braftovi,encorafenib,Extension,Yes,Pierre Fabre Medicament,26/07/2018,19/03/2024,Cancer,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,J05,Edurant,rilpivirine,Extension,No,Janssen-Cilag International N.V.,nan,28/10/2022,Infectives,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Mektovi,binimetinib,Extension,Yes,Pierre Fabre Medicament,nan,17/06/2024,Cancer,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Keytruda,pembrolizumab,Extension,Yes,Merck Sharp & Dohme B.V.,20/05/2015,08/07/2024,Cancer,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,C02,Opsumit,macitentan,Extension,No,Janssen-Cilag International N.V.,nan,01/12/2022,Cardiovascular,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Padcev,enfortumab vedotin,Extension,Yes,Astellas Pharma Europe B.V.,24/02/2022,29/11/2023,Cancer,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Rybrevant,amivantamab,Extension,Yes,Janssen-Cilag International N.V.,14/10/2021,27/06/2024,Cancer,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,N05,Slenyto,melatonin,Extension,No,RAD Neurim Pharmaceuticals EEC SARL,26/07/2018,16/02/2024,CNS,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L04,Spevigo,spesolimab,Extension,No,Boehringer Ingelheim International GmbH,13/10/2022,nan,Immuo-mod,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Tecentriq,atezolizumab,Extension,Yes,Roche Registration GmbH,19/07/2017,04/07/2024,Cancer,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,D11,Anzupgo,delgocitinib,Initial approval,No,LEO Pharma A/S,25/07/2024,nan,Dermatology,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,A05,Iqirvo,elafibranor,Initial approval,No,Ipsen Pharma,25/07/2024,nan,Alimentary,Yes,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,A05,Kayfanda,odevixibat,Initial approval,No,Ipsen Pharma,25/07/2024,nan,Alimentary,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Loqtorzi,toripalimab,Initial approval,Yes,TMC Pharma (EU) Limited,25/07/2024,nan,Cancer,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,S01,Vevizye,ciclosporin,Initial approval,No,Novaliq GmbH,25/07/2024,nan,Sense organs,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Vyloy,zolbetuximab,Initial approval,Yes,Astellas Pharma Europe B.V.,25/07/2024,nan,Cancer,Yes,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,C02,Yuvanci,macitentan / tadalafil,Initial approval,No,Janssen-Cilag International NV,25/07/2024,nan,Cardiovascular,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,J07,Arexvy,"Respiratory syncytial virus, glycoprotein F, recombinant, stabilised in the pre-fusion conformation, adjuvanted with AS01E",Extension,No,GlaxoSmithkline Biologicals S.A.,nan,27/06/2024,Infectives,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Braftovi,encorafenib,Extension,Yes,Pierre Fabre Medicament,26/07/2018,19/03/2024,Cancer,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,J05,Edurant,rilpivirine,Extension,No,Janssen-Cilag International N.V.,nan,28/10/2022,Infectives,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Mektovi,binimetinib,Extension,Yes,Pierre Fabre Medicament,nan,17/06/2024,Cancer,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Keytruda,pembrolizumab,Extension,Yes,Merck Sharp & Dohme B.V.,20/05/2015,08/07/2024,Cancer,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,C02,Opsumit,macitentan,Extension,No,Janssen-Cilag International N.V.,nan,01/12/2022,Cardiovascular,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Padcev,enfortumab vedotin,Extension,Yes,Astellas Pharma Europe B.V.,24/02/2022,29/11/2023,Cancer,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Rybrevant,amivantamab,Extension,Yes,Janssen-Cilag International N.V.,14/10/2021,27/06/2024,Cancer,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,N05,Slenyto,melatonin,Extension,No,RAD Neurim Pharmaceuticals EEC SARL,26/07/2018,16/02/2024,CNS,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L04,Spevigo,spesolimab,Extension,No,Boehringer Ingelheim International GmbH,13/10/2022,nan,Immuo-mod,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Tecentriq,atezolizumab,Extension,Yes,Roche Registration GmbH,19/07/2017,04/07/2024,Cancer,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,D11,Anzupgo,delgocitinib,Initial approval,No,LEO Pharma A/S,25/07/2024,nan,Dermatology,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,A05,Iqirvo,elafibranor,Initial approval,No,Ipsen Pharma,25/07/2024,nan,Alimentary,Yes,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,A05,Kayfanda,odevixibat,Initial approval,No,Ipsen Pharma,25/07/2024,nan,Alimentary,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Loqtorzi,toripalimab,Initial approval,Yes,TMC Pharma (EU) Limited,25/07/2024,nan,Cancer,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,S01,Vevizye,ciclosporin,Initial approval,No,Novaliq GmbH,25/07/2024,nan,Sense organs,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Vyloy,zolbetuximab,Initial approval,Yes,Astellas Pharma Europe B.V.,25/07/2024,nan,Cancer,Yes,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,C02,Yuvanci,macitentan / tadalafil,Initial approval,No,Janssen-Cilag International NV,25/07/2024,nan,Cardiovascular,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,J07,Arexvy,"Respiratory syncytial virus, glycoprotein F, recombinant, stabilised in the pre-fusion conformation, adjuvanted with AS01E",Extension,No,GlaxoSmithkline Biologicals S.A.,nan,27/06/2024,Infectives,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Braftovi,encorafenib,Extension,Yes,Pierre Fabre Medicament,26/07/2018,19/03/2024,Cancer,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,J05,Edurant,rilpivirine,Extension,No,Janssen-Cilag International N.V.,nan,28/10/2022,Infectives,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Mektovi,binimetinib,Extension,Yes,Pierre Fabre Medicament,nan,17/06/2024,Cancer,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Keytruda,pembrolizumab,Extension,Yes,Merck Sharp & Dohme B.V.,20/05/2015,08/07/2024,Cancer,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,C02,Opsumit,macitentan,Extension,No,Janssen-Cilag International N.V.,nan,01/12/2022,Cardiovascular,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Padcev,enfortumab vedotin,Extension,Yes,Astellas Pharma Europe B.V.,24/02/2022,29/11/2023,Cancer,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Rybrevant,amivantamab,Extension,Yes,Janssen-Cilag International N.V.,14/10/2021,27/06/2024,Cancer,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,N05,Slenyto,melatonin,Extension,No,RAD Neurim Pharmaceuticals EEC SARL,26/07/2018,16/02/2024,CNS,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L04,Spevigo,spesolimab,Extension,No,Boehringer Ingelheim International GmbH,13/10/2022,nan,Immuo-mod,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Tecentriq,atezolizumab,Extension,Yes,Roche Registration GmbH,19/07/2017,04/07/2024,Cancer,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,D11,Anzupgo,delgocitinib,Initial approval,No,LEO Pharma A/S,25/07/2024,nan,Dermatology,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,A05,Iqirvo,elafibranor,Initial approval,No,Ipsen Pharma,25/07/2024,nan,Alimentary,Yes,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,A05,Kayfanda,odevixibat,Initial approval,No,Ipsen Pharma,25/07/2024,nan,Alimentary,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Loqtorzi,toripalimab,Initial approval,Yes,TMC Pharma (EU) Limited,25/07/2024,nan,Cancer,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,S01,Vevizye,ciclosporin,Initial approval,No,Novaliq GmbH,25/07/2024,nan,Sense organs,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Vyloy,zolbetuximab,Initial approval,Yes,Astellas Pharma Europe B.V.,25/07/2024,nan,Cancer,Yes,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,C02,Yuvanci,macitentan / tadalafil,Initial approval,No,Janssen-Cilag International NV,25/07/2024,nan,Cardiovascular,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,J07,Arexvy,"Respiratory syncytial virus, glycoprotein F, recombinant, stabilised in the pre-fusion conformation, adjuvanted with AS01E",Extension,No,GlaxoSmithkline Biologicals S.A.,nan,27/06/2024,Infectives,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Braftovi,encorafenib,Extension,Yes,Pierre Fabre Medicament,26/07/2018,19/03/2024,Cancer,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,J05,Edurant,rilpivirine,Extension,No,Janssen-Cilag International N.V.,nan,28/10/2022,Infectives,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Mektovi,binimetinib,Extension,Yes,Pierre Fabre Medicament,nan,17/06/2024,Cancer,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Keytruda,pembrolizumab,Extension,Yes,Merck Sharp & Dohme B.V.,20/05/2015,08/07/2024,Cancer,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,C02,Opsumit,macitentan,Extension,No,Janssen-Cilag International N.V.,nan,01/12/2022,Cardiovascular,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Padcev,enfortumab vedotin,Extension,Yes,Astellas Pharma Europe B.V.,24/02/2022,29/11/2023,Cancer,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Rybrevant,amivantamab,Extension,Yes,Janssen-Cilag International N.V.,14/10/2021,27/06/2024,Cancer,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,N05,Slenyto,melatonin,Extension,No,RAD Neurim Pharmaceuticals EEC SARL,26/07/2018,16/02/2024,CNS,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L04,Spevigo,spesolimab,Extension,No,Boehringer Ingelheim International GmbH,13/10/2022,nan,Immuo-mod,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Tecentriq,atezolizumab,Extension,Yes,Roche Registration GmbH,19/07/2017,04/07/2024,Cancer,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,D11,Anzupgo,delgocitinib,Initial approval,No,LEO Pharma A/S,25/07/2024,nan,Dermatology,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,A05,Iqirvo,elafibranor,Initial approval,No,Ipsen Pharma,25/07/2024,nan,Alimentary,Yes,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,A05,Kayfanda,odevixibat,Initial approval,No,Ipsen Pharma,25/07/2024,nan,Alimentary,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Loqtorzi,toripalimab,Initial approval,Yes,TMC Pharma (EU) Limited,25/07/2024,nan,Cancer,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,S01,Vevizye,ciclosporin,Initial approval,No,Novaliq GmbH,25/07/2024,nan,Sense organs,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Vyloy,zolbetuximab,Initial approval,Yes,Astellas Pharma Europe B.V.,25/07/2024,nan,Cancer,Yes,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,C02,Yuvanci,macitentan / tadalafil,Initial approval,No,Janssen-Cilag International NV,25/07/2024,nan,Cardiovascular,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,J07,Arexvy,"Respiratory syncytial virus, glycoprotein F, recombinant, stabilised in the pre-fusion conformation, adjuvanted with AS01E",Extension,No,GlaxoSmithkline Biologicals S.A.,nan,27/06/2024,Infectives,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Braftovi,encorafenib,Extension,Yes,Pierre Fabre Medicament,26/07/2018,19/03/2024,Cancer,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,J05,Edurant,rilpivirine,Extension,No,Janssen-Cilag International N.V.,nan,28/10/2022,Infectives,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Mektovi,binimetinib,Extension,Yes,Pierre Fabre Medicament,nan,17/06/2024,Cancer,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Keytruda,pembrolizumab,Extension,Yes,Merck Sharp & Dohme B.V.,20/05/2015,08/07/2024,Cancer,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,C02,Opsumit,macitentan,Extension,No,Janssen-Cilag International N.V.,nan,01/12/2022,Cardiovascular,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Padcev,enfortumab vedotin,Extension,Yes,Astellas Pharma Europe B.V.,24/02/2022,29/11/2023,Cancer,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Rybrevant,amivantamab,Extension,Yes,Janssen-Cilag International N.V.,14/10/2021,27/06/2024,Cancer,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,N05,Slenyto,melatonin,Extension,No,RAD Neurim Pharmaceuticals EEC SARL,26/07/2018,16/02/2024,CNS,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L04,Spevigo,spesolimab,Extension,No,Boehringer Ingelheim International GmbH,13/10/2022,nan,Immuo-mod,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Tecentriq,atezolizumab,Extension,Yes,Roche Registration GmbH,19/07/2017,04/07/2024,Cancer,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,D11,Anzupgo,delgocitinib,Initial approval,No,LEO Pharma A/S,25/07/2024,nan,Dermatology,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,A05,Iqirvo,elafibranor,Initial approval,No,Ipsen Pharma,25/07/2024,nan,Alimentary,Yes,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,A05,Kayfanda,odevixibat,Initial approval,No,Ipsen Pharma,25/07/2024,nan,Alimentary,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Loqtorzi,toripalimab,Initial approval,Yes,TMC Pharma (EU) Limited,25/07/2024,nan,Cancer,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,S01,Vevizye,ciclosporin,Initial approval,No,Novaliq GmbH,25/07/2024,nan,Sense organs,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Vyloy,zolbetuximab,Initial approval,Yes,Astellas Pharma Europe B.V.,25/07/2024,nan,Cancer,Yes,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,C02,Yuvanci,macitentan / tadalafil,Initial approval,No,Janssen-Cilag International NV,25/07/2024,nan,Cardiovascular,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,J07,Arexvy,"Respiratory syncytial virus, glycoprotein F, recombinant, stabilised in the pre-fusion conformation, adjuvanted with AS01E",Extension,No,GlaxoSmithkline Biologicals S.A.,nan,27/06/2024,Infectives,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Braftovi,encorafenib,Extension,Yes,Pierre Fabre Medicament,26/07/2018,19/03/2024,Cancer,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,J05,Edurant,rilpivirine,Extension,No,Janssen-Cilag International N.V.,nan,28/10/2022,Infectives,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Mektovi,binimetinib,Extension,Yes,Pierre Fabre Medicament,nan,17/06/2024,Cancer,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Keytruda,pembrolizumab,Extension,Yes,Merck Sharp & Dohme B.V.,20/05/2015,08/07/2024,Cancer,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,C02,Opsumit,macitentan,Extension,No,Janssen-Cilag International N.V.,nan,01/12/2022,Cardiovascular,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Padcev,enfortumab vedotin,Extension,Yes,Astellas Pharma Europe B.V.,24/02/2022,29/11/2023,Cancer,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Rybrevant,amivantamab,Extension,Yes,Janssen-Cilag International N.V.,14/10/2021,27/06/2024,Cancer,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,N05,Slenyto,melatonin,Extension,No,RAD Neurim Pharmaceuticals EEC SARL,26/07/2018,16/02/2024,CNS,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L04,Spevigo,spesolimab,Extension,No,Boehringer Ingelheim International GmbH,13/10/2022,nan,Immuo-mod,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Tecentriq,atezolizumab,Extension,Yes,Roche Registration GmbH,19/07/2017,04/07/2024,Cancer,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,D11,Anzupgo,delgocitinib,Initial approval,No,LEO Pharma A/S,25/07/2024,nan,Dermatology,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,A05,Iqirvo,elafibranor,Initial approval,No,Ipsen Pharma,25/07/2024,nan,Alimentary,Yes,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,A05,Kayfanda,odevixibat,Initial approval,No,Ipsen Pharma,25/07/2024,nan,Alimentary,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Loqtorzi,toripalimab,Initial approval,Yes,TMC Pharma (EU) Limited,25/07/2024,nan,Cancer,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,S01,Vevizye,ciclosporin,Initial approval,No,Novaliq GmbH,25/07/2024,nan,Sense organs,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Vyloy,zolbetuximab,Initial approval,Yes,Astellas Pharma Europe B.V.,25/07/2024,nan,Cancer,Yes,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,C02,Yuvanci,macitentan / tadalafil,Initial approval,No,Janssen-Cilag International NV,25/07/2024,nan,Cardiovascular,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,J07,Arexvy,"Respiratory syncytial virus, glycoprotein F, recombinant, stabilised in the pre-fusion conformation, adjuvanted with AS01E",Extension,No,GlaxoSmithkline Biologicals S.A.,nan,27/06/2024,Infectives,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Braftovi,encorafenib,Extension,Yes,Pierre Fabre Medicament,26/07/2018,19/03/2024,Cancer,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,J05,Edurant,rilpivirine,Extension,No,Janssen-Cilag International N.V.,nan,28/10/2022,Infectives,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Mektovi,binimetinib,Extension,Yes,Pierre Fabre Medicament,nan,17/06/2024,Cancer,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Keytruda,pembrolizumab,Extension,Yes,Merck Sharp & Dohme B.V.,20/05/2015,08/07/2024,Cancer,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,C02,Opsumit,macitentan,Extension,No,Janssen-Cilag International N.V.,nan,01/12/2022,Cardiovascular,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Padcev,enfortumab vedotin,Extension,Yes,Astellas Pharma Europe B.V.,24/02/2022,29/11/2023,Cancer,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Rybrevant,amivantamab,Extension,Yes,Janssen-Cilag International N.V.,14/10/2021,27/06/2024,Cancer,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,N05,Slenyto,melatonin,Extension,No,RAD Neurim Pharmaceuticals EEC SARL,26/07/2018,16/02/2024,CNS,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L04,Spevigo,spesolimab,Extension,No,Boehringer Ingelheim International GmbH,13/10/2022,nan,Immuo-mod,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Tecentriq,atezolizumab,Extension,Yes,Roche Registration GmbH,19/07/2017,04/07/2024,Cancer,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,D11,Anzupgo,delgocitinib,Initial approval,No,LEO Pharma A/S,25/07/2024,nan,Dermatology,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,A05,Iqirvo,elafibranor,Initial approval,No,Ipsen Pharma,25/07/2024,nan,Alimentary,Yes,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,A05,Kayfanda,odevixibat,Initial approval,No,Ipsen Pharma,25/07/2024,nan,Alimentary,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Loqtorzi,toripalimab,Initial approval,Yes,TMC Pharma (EU) Limited,25/07/2024,nan,Cancer,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,S01,Vevizye,ciclosporin,Initial approval,No,Novaliq GmbH,25/07/2024,nan,Sense organs,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Vyloy,zolbetuximab,Initial approval,Yes,Astellas Pharma Europe B.V.,25/07/2024,nan,Cancer,Yes,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,C02,Yuvanci,macitentan / tadalafil,Initial approval,No,Janssen-Cilag International NV,25/07/2024,nan,Cardiovascular,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,J07,Arexvy,"Respiratory syncytial virus, glycoprotein F, recombinant, stabilised in the pre-fusion conformation, adjuvanted with AS01E",Extension,No,GlaxoSmithkline Biologicals S.A.,nan,27/06/2024,Infectives,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Braftovi,encorafenib,Extension,Yes,Pierre Fabre Medicament,26/07/2018,19/03/2024,Cancer,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,J05,Edurant,rilpivirine,Extension,No,Janssen-Cilag International N.V.,nan,28/10/2022,Infectives,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Mektovi,binimetinib,Extension,Yes,Pierre Fabre Medicament,nan,17/06/2024,Cancer,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Keytruda,pembrolizumab,Extension,Yes,Merck Sharp & Dohme B.V.,20/05/2015,08/07/2024,Cancer,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,C02,Opsumit,macitentan,Extension,No,Janssen-Cilag International N.V.,nan,01/12/2022,Cardiovascular,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Padcev,enfortumab vedotin,Extension,Yes,Astellas Pharma Europe B.V.,24/02/2022,29/11/2023,Cancer,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Rybrevant,amivantamab,Extension,Yes,Janssen-Cilag International N.V.,14/10/2021,27/06/2024,Cancer,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,N05,Slenyto,melatonin,Extension,No,RAD Neurim Pharmaceuticals EEC SARL,26/07/2018,16/02/2024,CNS,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L04,Spevigo,spesolimab,Extension,No,Boehringer Ingelheim International GmbH,13/10/2022,nan,Immuo-mod,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Tecentriq,atezolizumab,Extension,Yes,Roche Registration GmbH,19/07/2017,04/07/2024,Cancer,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,D11,Anzupgo,delgocitinib,Initial approval,No,LEO Pharma A/S,25/07/2024,nan,Dermatology,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,A05,Iqirvo,elafibranor,Initial approval,No,Ipsen Pharma,25/07/2024,nan,Alimentary,Yes,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,A05,Kayfanda,odevixibat,Initial approval,No,Ipsen Pharma,25/07/2024,nan,Alimentary,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Loqtorzi,toripalimab,Initial approval,Yes,TMC Pharma (EU) Limited,25/07/2024,nan,Cancer,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,S01,Vevizye,ciclosporin,Initial approval,No,Novaliq GmbH,25/07/2024,nan,Sense organs,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Vyloy,zolbetuximab,Initial approval,Yes,Astellas Pharma Europe B.V.,25/07/2024,nan,Cancer,Yes,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,C02,Yuvanci,macitentan / tadalafil,Initial approval,No,Janssen-Cilag International NV,25/07/2024,nan,Cardiovascular,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,J07,Arexvy,"Respiratory syncytial virus, glycoprotein F, recombinant, stabilised in the pre-fusion conformation, adjuvanted with AS01E",Extension,No,GlaxoSmithkline Biologicals S.A.,nan,27/06/2024,Infectives,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Braftovi,encorafenib,Extension,Yes,Pierre Fabre Medicament,26/07/2018,19/03/2024,Cancer,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,J05,Edurant,rilpivirine,Extension,No,Janssen-Cilag International N.V.,nan,28/10/2022,Infectives,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Mektovi,binimetinib,Extension,Yes,Pierre Fabre Medicament,nan,17/06/2024,Cancer,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Keytruda,pembrolizumab,Extension,Yes,Merck Sharp & Dohme B.V.,20/05/2015,08/07/2024,Cancer,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,C02,Opsumit,macitentan,Extension,No,Janssen-Cilag International N.V.,nan,01/12/2022,Cardiovascular,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Padcev,enfortumab vedotin,Extension,Yes,Astellas Pharma Europe B.V.,24/02/2022,29/11/2023,Cancer,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Rybrevant,amivantamab,Extension,Yes,Janssen-Cilag International N.V.,14/10/2021,27/06/2024,Cancer,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,N05,Slenyto,melatonin,Extension,No,RAD Neurim Pharmaceuticals EEC SARL,26/07/2018,16/02/2024,CNS,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L04,Spevigo,spesolimab,Extension,No,Boehringer Ingelheim International GmbH,13/10/2022,nan,Immuo-mod,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Tecentriq,atezolizumab,Extension,Yes,Roche Registration GmbH,19/07/2017,04/07/2024,Cancer,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,D11,Anzupgo,delgocitinib,Initial approval,No,LEO Pharma A/S,25/07/2024,nan,Dermatology,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,A05,Iqirvo,elafibranor,Initial approval,No,Ipsen Pharma,25/07/2024,nan,Alimentary,Yes,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,A05,Kayfanda,odevixibat,Initial approval,No,Ipsen Pharma,25/07/2024,nan,Alimentary,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Loqtorzi,toripalimab,Initial approval,Yes,TMC Pharma (EU) Limited,25/07/2024,nan,Cancer,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,S01,Vevizye,ciclosporin,Initial approval,No,Novaliq GmbH,25/07/2024,nan,Sense organs,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Vyloy,zolbetuximab,Initial approval,Yes,Astellas Pharma Europe B.V.,25/07/2024,nan,Cancer,Yes,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,C02,Yuvanci,macitentan / tadalafil,Initial approval,No,Janssen-Cilag International NV,25/07/2024,nan,Cardiovascular,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,J07,Arexvy,"Respiratory syncytial virus, glycoprotein F, recombinant, stabilised in the pre-fusion conformation, adjuvanted with AS01E",Extension,No,GlaxoSmithkline Biologicals S.A.,nan,27/06/2024,Infectives,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Braftovi,encorafenib,Extension,Yes,Pierre Fabre Medicament,26/07/2018,19/03/2024,Cancer,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,J05,Edurant,rilpivirine,Extension,No,Janssen-Cilag International N.V.,nan,28/10/2022,Infectives,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Mektovi,binimetinib,Extension,Yes,Pierre Fabre Medicament,nan,17/06/2024,Cancer,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Keytruda,pembrolizumab,Extension,Yes,Merck Sharp & Dohme B.V.,20/05/2015,08/07/2024,Cancer,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,C02,Opsumit,macitentan,Extension,No,Janssen-Cilag International N.V.,nan,01/12/2022,Cardiovascular,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Padcev,enfortumab vedotin,Extension,Yes,Astellas Pharma Europe B.V.,24/02/2022,29/11/2023,Cancer,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Rybrevant,amivantamab,Extension,Yes,Janssen-Cilag International N.V.,14/10/2021,27/06/2024,Cancer,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,N05,Slenyto,melatonin,Extension,No,RAD Neurim Pharmaceuticals EEC SARL,26/07/2018,16/02/2024,CNS,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L04,Spevigo,spesolimab,Extension,No,Boehringer Ingelheim International GmbH,13/10/2022,nan,Immuo-mod,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Tecentriq,atezolizumab,Extension,Yes,Roche Registration GmbH,19/07/2017,04/07/2024,Cancer,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,D11,Anzupgo,delgocitinib,Initial approval,No,LEO Pharma A/S,25/07/2024,nan,Dermatology,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,A05,Iqirvo,elafibranor,Initial approval,No,Ipsen Pharma,25/07/2024,nan,Alimentary,Yes,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,A05,Kayfanda,odevixibat,Initial approval,No,Ipsen Pharma,25/07/2024,nan,Alimentary,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Loqtorzi,toripalimab,Initial approval,Yes,TMC Pharma (EU) Limited,25/07/2024,nan,Cancer,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,S01,Vevizye,ciclosporin,Initial approval,No,Novaliq GmbH,25/07/2024,nan,Sense organs,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Vyloy,zolbetuximab,Initial approval,Yes,Astellas Pharma Europe B.V.,25/07/2024,nan,Cancer,Yes,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,C02,Yuvanci,macitentan / tadalafil,Initial approval,No,Janssen-Cilag International NV,25/07/2024,nan,Cardiovascular,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,J07,Arexvy,"Respiratory syncytial virus, glycoprotein F, recombinant, stabilised in the pre-fusion conformation, adjuvanted with AS01E",Extension,No,GlaxoSmithkline Biologicals S.A.,nan,27/06/2024,Infectives,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Braftovi,encorafenib,Extension,Yes,Pierre Fabre Medicament,26/07/2018,19/03/2024,Cancer,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,J05,Edurant,rilpivirine,Extension,No,Janssen-Cilag International N.V.,nan,28/10/2022,Infectives,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Mektovi,binimetinib,Extension,Yes,Pierre Fabre Medicament,nan,17/06/2024,Cancer,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Keytruda,pembrolizumab,Extension,Yes,Merck Sharp & Dohme B.V.,20/05/2015,08/07/2024,Cancer,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,C02,Opsumit,macitentan,Extension,No,Janssen-Cilag International N.V.,nan,01/12/2022,Cardiovascular,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Padcev,enfortumab vedotin,Extension,Yes,Astellas Pharma Europe B.V.,24/02/2022,29/11/2023,Cancer,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Rybrevant,amivantamab,Extension,Yes,Janssen-Cilag International N.V.,14/10/2021,27/06/2024,Cancer,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,N05,Slenyto,melatonin,Extension,No,RAD Neurim Pharmaceuticals EEC SARL,26/07/2018,16/02/2024,CNS,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L04,Spevigo,spesolimab,Extension,No,Boehringer Ingelheim International GmbH,13/10/2022,nan,Immuo-mod,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Tecentriq,atezolizumab,Extension,Yes,Roche Registration GmbH,19/07/2017,04/07/2024,Cancer,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,D11,Anzupgo,delgocitinib,Initial approval,No,LEO Pharma A/S,25/07/2024,nan,Dermatology,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,A05,Iqirvo,elafibranor,Initial approval,No,Ipsen Pharma,25/07/2024,nan,Alimentary,Yes,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,A05,Kayfanda,odevixibat,Initial approval,No,Ipsen Pharma,25/07/2024,nan,Alimentary,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Loqtorzi,toripalimab,Initial approval,Yes,TMC Pharma (EU) Limited,25/07/2024,nan,Cancer,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,S01,Vevizye,ciclosporin,Initial approval,No,Novaliq GmbH,25/07/2024,nan,Sense organs,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Vyloy,zolbetuximab,Initial approval,Yes,Astellas Pharma Europe B.V.,25/07/2024,nan,Cancer,Yes,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,C02,Yuvanci,macitentan / tadalafil,Initial approval,No,Janssen-Cilag International NV,25/07/2024,nan,Cardiovascular,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,J07,Arexvy,"Respiratory syncytial virus, glycoprotein F, recombinant, stabilised in the pre-fusion conformation, adjuvanted with AS01E",Extension,No,GlaxoSmithkline Biologicals S.A.,nan,27/06/2024,Infectives,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Braftovi,encorafenib,Extension,Yes,Pierre Fabre Medicament,26/07/2018,19/03/2024,Cancer,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,J05,Edurant,rilpivirine,Extension,No,Janssen-Cilag International N.V.,nan,28/10/2022,Infectives,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Mektovi,binimetinib,Extension,Yes,Pierre Fabre Medicament,nan,17/06/2024,Cancer,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Keytruda,pembrolizumab,Extension,Yes,Merck Sharp & Dohme B.V.,20/05/2015,08/07/2024,Cancer,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,C02,Opsumit,macitentan,Extension,No,Janssen-Cilag International N.V.,nan,01/12/2022,Cardiovascular,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Padcev,enfortumab vedotin,Extension,Yes,Astellas Pharma Europe B.V.,24/02/2022,29/11/2023,Cancer,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Rybrevant,amivantamab,Extension,Yes,Janssen-Cilag International N.V.,14/10/2021,27/06/2024,Cancer,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,N05,Slenyto,melatonin,Extension,No,RAD Neurim Pharmaceuticals EEC SARL,26/07/2018,16/02/2024,CNS,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L04,Spevigo,spesolimab,Extension,No,Boehringer Ingelheim International GmbH,13/10/2022,nan,Immuo-mod,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Tecentriq,atezolizumab,Extension,Yes,Roche Registration GmbH,19/07/2017,04/07/2024,Cancer,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,D11,Anzupgo,delgocitinib,Initial approval,No,LEO Pharma A/S,25/07/2024,nan,Dermatology,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,A05,Iqirvo,elafibranor,Initial approval,No,Ipsen Pharma,25/07/2024,nan,Alimentary,Yes,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,A05,Kayfanda,odevixibat,Initial approval,No,Ipsen Pharma,25/07/2024,nan,Alimentary,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Loqtorzi,toripalimab,Initial approval,Yes,TMC Pharma (EU) Limited,25/07/2024,nan,Cancer,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,S01,Vevizye,ciclosporin,Initial approval,No,Novaliq GmbH,25/07/2024,nan,Sense organs,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Vyloy,zolbetuximab,Initial approval,Yes,Astellas Pharma Europe B.V.,25/07/2024,nan,Cancer,Yes,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,C02,Yuvanci,macitentan / tadalafil,Initial approval,No,Janssen-Cilag International NV,25/07/2024,nan,Cardiovascular,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,J07,Arexvy,"Respiratory syncytial virus, glycoprotein F, recombinant, stabilised in the pre-fusion conformation, adjuvanted with AS01E",Extension,No,GlaxoSmithkline Biologicals S.A.,nan,27/06/2024,Infectives,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Braftovi,encorafenib,Extension,Yes,Pierre Fabre Medicament,26/07/2018,19/03/2024,Cancer,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,J05,Edurant,rilpivirine,Extension,No,Janssen-Cilag International N.V.,nan,28/10/2022,Infectives,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Mektovi,binimetinib,Extension,Yes,Pierre Fabre Medicament,nan,17/06/2024,Cancer,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Keytruda,pembrolizumab,Extension,Yes,Merck Sharp & Dohme B.V.,20/05/2015,08/07/2024,Cancer,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,C02,Opsumit,macitentan,Extension,No,Janssen-Cilag International N.V.,nan,01/12/2022,Cardiovascular,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Padcev,enfortumab vedotin,Extension,Yes,Astellas Pharma Europe B.V.,24/02/2022,29/11/2023,Cancer,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Rybrevant,amivantamab,Extension,Yes,Janssen-Cilag International N.V.,14/10/2021,27/06/2024,Cancer,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,N05,Slenyto,melatonin,Extension,No,RAD Neurim Pharmaceuticals EEC SARL,26/07/2018,16/02/2024,CNS,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L04,Spevigo,spesolimab,Extension,No,Boehringer Ingelheim International GmbH,13/10/2022,nan,Immuo-mod,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Tecentriq,atezolizumab,Extension,Yes,Roche Registration GmbH,19/07/2017,04/07/2024,Cancer,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,D11,Anzupgo,delgocitinib,Initial approval,No,LEO Pharma A/S,25/07/2024,nan,Dermatology,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,A05,Iqirvo,elafibranor,Initial approval,No,Ipsen Pharma,25/07/2024,nan,Alimentary,Yes,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,A05,Kayfanda,odevixibat,Initial approval,No,Ipsen Pharma,25/07/2024,nan,Alimentary,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Loqtorzi,toripalimab,Initial approval,Yes,TMC Pharma (EU) Limited,25/07/2024,nan,Cancer,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,S01,Vevizye,ciclosporin,Initial approval,No,Novaliq GmbH,25/07/2024,nan,Sense organs,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Vyloy,zolbetuximab,Initial approval,Yes,Astellas Pharma Europe B.V.,25/07/2024,nan,Cancer,Yes,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,C02,Yuvanci,macitentan / tadalafil,Initial approval,No,Janssen-Cilag International NV,25/07/2024,nan,Cardiovascular,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,J07,Arexvy,"Respiratory syncytial virus, glycoprotein F, recombinant, stabilised in the pre-fusion conformation, adjuvanted with AS01E",Extension,No,GlaxoSmithkline Biologicals S.A.,nan,27/06/2024,Infectives,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Braftovi,encorafenib,Extension,Yes,Pierre Fabre Medicament,26/07/2018,19/03/2024,Cancer,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,J05,Edurant,rilpivirine,Extension,No,Janssen-Cilag International N.V.,nan,28/10/2022,Infectives,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Mektovi,binimetinib,Extension,Yes,Pierre Fabre Medicament,nan,17/06/2024,Cancer,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Keytruda,pembrolizumab,Extension,Yes,Merck Sharp & Dohme B.V.,20/05/2015,08/07/2024,Cancer,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,C02,Opsumit,macitentan,Extension,No,Janssen-Cilag International N.V.,nan,01/12/2022,Cardiovascular,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Padcev,enfortumab vedotin,Extension,Yes,Astellas Pharma Europe B.V.,24/02/2022,29/11/2023,Cancer,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Rybrevant,amivantamab,Extension,Yes,Janssen-Cilag International N.V.,14/10/2021,27/06/2024,Cancer,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,N05,Slenyto,melatonin,Extension,No,RAD Neurim Pharmaceuticals EEC SARL,26/07/2018,16/02/2024,CNS,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L04,Spevigo,spesolimab,Extension,No,Boehringer Ingelheim International GmbH,13/10/2022,nan,Immuo-mod,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Tecentriq,atezolizumab,Extension,Yes,Roche Registration GmbH,19/07/2017,04/07/2024,Cancer,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,D11,Anzupgo,delgocitinib,Initial approval,No,LEO Pharma A/S,25/07/2024,nan,Dermatology,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,A05,Iqirvo,elafibranor,Initial approval,No,Ipsen Pharma,25/07/2024,nan,Alimentary,Yes,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,A05,Kayfanda,odevixibat,Initial approval,No,Ipsen Pharma,25/07/2024,nan,Alimentary,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Loqtorzi,toripalimab,Initial approval,Yes,TMC Pharma (EU) Limited,25/07/2024,nan,Cancer,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,S01,Vevizye,ciclosporin,Initial approval,No,Novaliq GmbH,25/07/2024,nan,Sense organs,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Vyloy,zolbetuximab,Initial approval,Yes,Astellas Pharma Europe B.V.,25/07/2024,nan,Cancer,Yes,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,C02,Yuvanci,macitentan / tadalafil,Initial approval,No,Janssen-Cilag International NV,25/07/2024,nan,Cardiovascular,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,J07,Arexvy,"Respiratory syncytial virus, glycoprotein F, recombinant, stabilised in the pre-fusion conformation, adjuvanted with AS01E",Extension,No,GlaxoSmithkline Biologicals S.A.,nan,27/06/2024,Infectives,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Braftovi,encorafenib,Extension,Yes,Pierre Fabre Medicament,26/07/2018,19/03/2024,Cancer,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,J05,Edurant,rilpivirine,Extension,No,Janssen-Cilag International N.V.,nan,28/10/2022,Infectives,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Mektovi,binimetinib,Extension,Yes,Pierre Fabre Medicament,nan,17/06/2024,Cancer,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Keytruda,pembrolizumab,Extension,Yes,Merck Sharp & Dohme B.V.,20/05/2015,08/07/2024,Cancer,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,C02,Opsumit,macitentan,Extension,No,Janssen-Cilag International N.V.,nan,01/12/2022,Cardiovascular,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Padcev,enfortumab vedotin,Extension,Yes,Astellas Pharma Europe B.V.,24/02/2022,29/11/2023,Cancer,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Rybrevant,amivantamab,Extension,Yes,Janssen-Cilag International N.V.,14/10/2021,27/06/2024,Cancer,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,N05,Slenyto,melatonin,Extension,No,RAD Neurim Pharmaceuticals EEC SARL,26/07/2018,16/02/2024,CNS,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L04,Spevigo,spesolimab,Extension,No,Boehringer Ingelheim International GmbH,13/10/2022,nan,Immuo-mod,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Tecentriq,atezolizumab,Extension,Yes,Roche Registration GmbH,19/07/2017,04/07/2024,Cancer,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,D11,Anzupgo,delgocitinib,Initial approval,No,LEO Pharma A/S,25/07/2024,nan,Dermatology,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,A05,Iqirvo,elafibranor,Initial approval,No,Ipsen Pharma,25/07/2024,nan,Alimentary,Yes,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,A05,Kayfanda,odevixibat,Initial approval,No,Ipsen Pharma,25/07/2024,nan,Alimentary,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Loqtorzi,toripalimab,Initial approval,Yes,TMC Pharma (EU) Limited,25/07/2024,nan,Cancer,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,S01,Vevizye,ciclosporin,Initial approval,No,Novaliq GmbH,25/07/2024,nan,Sense organs,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Vyloy,zolbetuximab,Initial approval,Yes,Astellas Pharma Europe B.V.,25/07/2024,nan,Cancer,Yes,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,C02,Yuvanci,macitentan / tadalafil,Initial approval,No,Janssen-Cilag International NV,25/07/2024,nan,Cardiovascular,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,J07,Arexvy,"Respiratory syncytial virus, glycoprotein F, recombinant, stabilised in the pre-fusion conformation, adjuvanted with AS01E",Extension,No,GlaxoSmithkline Biologicals S.A.,nan,27/06/2024,Infectives,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Braftovi,encorafenib,Extension,Yes,Pierre Fabre Medicament,26/07/2018,19/03/2024,Cancer,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,J05,Edurant,rilpivirine,Extension,No,Janssen-Cilag International N.V.,nan,28/10/2022,Infectives,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Mektovi,binimetinib,Extension,Yes,Pierre Fabre Medicament,nan,17/06/2024,Cancer,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Keytruda,pembrolizumab,Extension,Yes,Merck Sharp & Dohme B.V.,20/05/2015,08/07/2024,Cancer,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,C02,Opsumit,macitentan,Extension,No,Janssen-Cilag International N.V.,nan,01/12/2022,Cardiovascular,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Padcev,enfortumab vedotin,Extension,Yes,Astellas Pharma Europe B.V.,24/02/2022,29/11/2023,Cancer,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Rybrevant,amivantamab,Extension,Yes,Janssen-Cilag International N.V.,14/10/2021,27/06/2024,Cancer,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,N05,Slenyto,melatonin,Extension,No,RAD Neurim Pharmaceuticals EEC SARL,26/07/2018,16/02/2024,CNS,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L04,Spevigo,spesolimab,Extension,No,Boehringer Ingelheim International GmbH,13/10/2022,nan,Immuo-mod,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Tecentriq,atezolizumab,Extension,Yes,Roche Registration GmbH,19/07/2017,04/07/2024,Cancer,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,D11,Anzupgo,delgocitinib,Initial approval,No,LEO Pharma A/S,25/07/2024,nan,Dermatology,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,A05,Iqirvo,elafibranor,Initial approval,No,Ipsen Pharma,25/07/2024,nan,Alimentary,Yes,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,A05,Kayfanda,odevixibat,Initial approval,No,Ipsen Pharma,25/07/2024,nan,Alimentary,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Loqtorzi,toripalimab,Initial approval,Yes,TMC Pharma (EU) Limited,25/07/2024,nan,Cancer,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,S01,Vevizye,ciclosporin,Initial approval,No,Novaliq GmbH,25/07/2024,nan,Sense organs,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Vyloy,zolbetuximab,Initial approval,Yes,Astellas Pharma Europe B.V.,25/07/2024,nan,Cancer,Yes,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,C02,Yuvanci,macitentan / tadalafil,Initial approval,No,Janssen-Cilag International NV,25/07/2024,nan,Cardiovascular,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,J07,Arexvy,"Respiratory syncytial virus, glycoprotein F, recombinant, stabilised in the pre-fusion conformation, adjuvanted with AS01E",Extension,No,GlaxoSmithkline Biologicals S.A.,nan,27/06/2024,Infectives,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Braftovi,encorafenib,Extension,Yes,Pierre Fabre Medicament,26/07/2018,19/03/2024,Cancer,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,J05,Edurant,rilpivirine,Extension,No,Janssen-Cilag International N.V.,nan,28/10/2022,Infectives,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Mektovi,binimetinib,Extension,Yes,Pierre Fabre Medicament,nan,17/06/2024,Cancer,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Keytruda,pembrolizumab,Extension,Yes,Merck Sharp & Dohme B.V.,20/05/2015,08/07/2024,Cancer,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,C02,Opsumit,macitentan,Extension,No,Janssen-Cilag International N.V.,nan,01/12/2022,Cardiovascular,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Padcev,enfortumab vedotin,Extension,Yes,Astellas Pharma Europe B.V.,24/02/2022,29/11/2023,Cancer,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Rybrevant,amivantamab,Extension,Yes,Janssen-Cilag International N.V.,14/10/2021,27/06/2024,Cancer,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,N05,Slenyto,melatonin,Extension,No,RAD Neurim Pharmaceuticals EEC SARL,26/07/2018,16/02/2024,CNS,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L04,Spevigo,spesolimab,Extension,No,Boehringer Ingelheim International GmbH,13/10/2022,nan,Immuo-mod,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Tecentriq,atezolizumab,Extension,Yes,Roche Registration GmbH,19/07/2017,04/07/2024,Cancer,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,D11,Anzupgo,delgocitinib,Initial approval,No,LEO Pharma A/S,25/07/2024,nan,Dermatology,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,A05,Iqirvo,elafibranor,Initial approval,No,Ipsen Pharma,25/07/2024,nan,Alimentary,Yes,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,A05,Kayfanda,odevixibat,Initial approval,No,Ipsen Pharma,25/07/2024,nan,Alimentary,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Loqtorzi,toripalimab,Initial approval,Yes,TMC Pharma (EU) Limited,25/07/2024,nan,Cancer,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,S01,Vevizye,ciclosporin,Initial approval,No,Novaliq GmbH,25/07/2024,nan,Sense organs,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Vyloy,zolbetuximab,Initial approval,Yes,Astellas Pharma Europe B.V.,25/07/2024,nan,Cancer,Yes,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,C02,Yuvanci,macitentan / tadalafil,Initial approval,No,Janssen-Cilag International NV,25/07/2024,nan,Cardiovascular,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,J07,Arexvy,"Respiratory syncytial virus, glycoprotein F, recombinant, stabilised in the pre-fusion conformation, adjuvanted with AS01E",Extension,No,GlaxoSmithkline Biologicals S.A.,nan,27/06/2024,Infectives,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Braftovi,encorafenib,Extension,Yes,Pierre Fabre Medicament,26/07/2018,19/03/2024,Cancer,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,J05,Edurant,rilpivirine,Extension,No,Janssen-Cilag International N.V.,nan,28/10/2022,Infectives,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Mektovi,binimetinib,Extension,Yes,Pierre Fabre Medicament,nan,17/06/2024,Cancer,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Keytruda,pembrolizumab,Extension,Yes,Merck Sharp & Dohme B.V.,20/05/2015,08/07/2024,Cancer,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,C02,Opsumit,macitentan,Extension,No,Janssen-Cilag International N.V.,nan,01/12/2022,Cardiovascular,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Padcev,enfortumab vedotin,Extension,Yes,Astellas Pharma Europe B.V.,24/02/2022,29/11/2023,Cancer,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Rybrevant,amivantamab,Extension,Yes,Janssen-Cilag International N.V.,14/10/2021,27/06/2024,Cancer,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,N05,Slenyto,melatonin,Extension,No,RAD Neurim Pharmaceuticals EEC SARL,26/07/2018,16/02/2024,CNS,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L04,Spevigo,spesolimab,Extension,No,Boehringer Ingelheim International GmbH,13/10/2022,nan,Immuo-mod,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Tecentriq,atezolizumab,Extension,Yes,Roche Registration GmbH,19/07/2017,04/07/2024,Cancer,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,D11,Anzupgo,delgocitinib,Initial approval,No,LEO Pharma A/S,25/07/2024,nan,Dermatology,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,A05,Iqirvo,elafibranor,Initial approval,No,Ipsen Pharma,25/07/2024,nan,Alimentary,Yes,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,A05,Kayfanda,odevixibat,Initial approval,No,Ipsen Pharma,25/07/2024,nan,Alimentary,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Loqtorzi,toripalimab,Initial approval,Yes,TMC Pharma (EU) Limited,25/07/2024,nan,Cancer,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,S01,Vevizye,ciclosporin,Initial approval,No,Novaliq GmbH,25/07/2024,nan,Sense organs,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Vyloy,zolbetuximab,Initial approval,Yes,Astellas Pharma Europe B.V.,25/07/2024,nan,Cancer,Yes,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,C02,Yuvanci,macitentan / tadalafil,Initial approval,No,Janssen-Cilag International NV,25/07/2024,nan,Cardiovascular,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,J07,Arexvy,"Respiratory syncytial virus, glycoprotein F, recombinant, stabilised in the pre-fusion conformation, adjuvanted with AS01E",Extension,No,GlaxoSmithkline Biologicals S.A.,nan,27/06/2024,Infectives,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Braftovi,encorafenib,Extension,Yes,Pierre Fabre Medicament,26/07/2018,19/03/2024,Cancer,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,J05,Edurant,rilpivirine,Extension,No,Janssen-Cilag International N.V.,nan,28/10/2022,Infectives,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Mektovi,binimetinib,Extension,Yes,Pierre Fabre Medicament,nan,17/06/2024,Cancer,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Keytruda,pembrolizumab,Extension,Yes,Merck Sharp & Dohme B.V.,20/05/2015,08/07/2024,Cancer,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,C02,Opsumit,macitentan,Extension,No,Janssen-Cilag International N.V.,nan,01/12/2022,Cardiovascular,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Padcev,enfortumab vedotin,Extension,Yes,Astellas Pharma Europe B.V.,24/02/2022,29/11/2023,Cancer,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Rybrevant,amivantamab,Extension,Yes,Janssen-Cilag International N.V.,14/10/2021,27/06/2024,Cancer,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,N05,Slenyto,melatonin,Extension,No,RAD Neurim Pharmaceuticals EEC SARL,26/07/2018,16/02/2024,CNS,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L04,Spevigo,spesolimab,Extension,No,Boehringer Ingelheim International GmbH,13/10/2022,nan,Immuo-mod,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Tecentriq,atezolizumab,Extension,Yes,Roche Registration GmbH,19/07/2017,04/07/2024,Cancer,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,D11,Anzupgo,delgocitinib,Initial approval,No,LEO Pharma A/S,25/07/2024,nan,Dermatology,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,A05,Iqirvo,elafibranor,Initial approval,No,Ipsen Pharma,25/07/2024,nan,Alimentary,Yes,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,A05,Kayfanda,odevixibat,Initial approval,No,Ipsen Pharma,25/07/2024,nan,Alimentary,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Loqtorzi,toripalimab,Initial approval,Yes,TMC Pharma (EU) Limited,25/07/2024,nan,Cancer,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,S01,Vevizye,ciclosporin,Initial approval,No,Novaliq GmbH,25/07/2024,nan,Sense organs,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Vyloy,zolbetuximab,Initial approval,Yes,Astellas Pharma Europe B.V.,25/07/2024,nan,Cancer,Yes,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,C02,Yuvanci,macitentan / tadalafil,Initial approval,No,Janssen-Cilag International NV,25/07/2024,nan,Cardiovascular,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,J07,Arexvy,"Respiratory syncytial virus, glycoprotein F, recombinant, stabilised in the pre-fusion conformation, adjuvanted with AS01E",Extension,No,GlaxoSmithkline Biologicals S.A.,nan,27/06/2024,Infectives,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Braftovi,encorafenib,Extension,Yes,Pierre Fabre Medicament,26/07/2018,19/03/2024,Cancer,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,J05,Edurant,rilpivirine,Extension,No,Janssen-Cilag International N.V.,nan,28/10/2022,Infectives,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Mektovi,binimetinib,Extension,Yes,Pierre Fabre Medicament,nan,17/06/2024,Cancer,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Keytruda,pembrolizumab,Extension,Yes,Merck Sharp & Dohme B.V.,20/05/2015,08/07/2024,Cancer,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,C02,Opsumit,macitentan,Extension,No,Janssen-Cilag International N.V.,nan,01/12/2022,Cardiovascular,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Padcev,enfortumab vedotin,Extension,Yes,Astellas Pharma Europe B.V.,24/02/2022,29/11/2023,Cancer,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Rybrevant,amivantamab,Extension,Yes,Janssen-Cilag International N.V.,14/10/2021,27/06/2024,Cancer,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,N05,Slenyto,melatonin,Extension,No,RAD Neurim Pharmaceuticals EEC SARL,26/07/2018,16/02/2024,CNS,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L04,Spevigo,spesolimab,Extension,No,Boehringer Ingelheim International GmbH,13/10/2022,nan,Immuo-mod,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Tecentriq,atezolizumab,Extension,Yes,Roche Registration GmbH,19/07/2017,04/07/2024,Cancer,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,D11,Anzupgo,delgocitinib,Initial approval,No,LEO Pharma A/S,25/07/2024,nan,Dermatology,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,A05,Iqirvo,elafibranor,Initial approval,No,Ipsen Pharma,25/07/2024,nan,Alimentary,Yes,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,A05,Kayfanda,odevixibat,Initial approval,No,Ipsen Pharma,25/07/2024,nan,Alimentary,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Loqtorzi,toripalimab,Initial approval,Yes,TMC Pharma (EU) Limited,25/07/2024,nan,Cancer,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,S01,Vevizye,ciclosporin,Initial approval,No,Novaliq GmbH,25/07/2024,nan,Sense organs,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Vyloy,zolbetuximab,Initial approval,Yes,Astellas Pharma Europe B.V.,25/07/2024,nan,Cancer,Yes,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,C02,Yuvanci,macitentan / tadalafil,Initial approval,No,Janssen-Cilag International NV,25/07/2024,nan,Cardiovascular,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,J07,Arexvy,"Respiratory syncytial virus, glycoprotein F, recombinant, stabilised in the pre-fusion conformation, adjuvanted with AS01E",Extension,No,GlaxoSmithkline Biologicals S.A.,nan,27/06/2024,Infectives,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Braftovi,encorafenib,Extension,Yes,Pierre Fabre Medicament,26/07/2018,19/03/2024,Cancer,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,J05,Edurant,rilpivirine,Extension,No,Janssen-Cilag International N.V.,nan,28/10/2022,Infectives,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Mektovi,binimetinib,Extension,Yes,Pierre Fabre Medicament,nan,17/06/2024,Cancer,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Keytruda,pembrolizumab,Extension,Yes,Merck Sharp & Dohme B.V.,20/05/2015,08/07/2024,Cancer,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,C02,Opsumit,macitentan,Extension,No,Janssen-Cilag International N.V.,nan,01/12/2022,Cardiovascular,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Padcev,enfortumab vedotin,Extension,Yes,Astellas Pharma Europe B.V.,24/02/2022,29/11/2023,Cancer,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Rybrevant,amivantamab,Extension,Yes,Janssen-Cilag International N.V.,14/10/2021,27/06/2024,Cancer,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,N05,Slenyto,melatonin,Extension,No,RAD Neurim Pharmaceuticals EEC SARL,26/07/2018,16/02/2024,CNS,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L04,Spevigo,spesolimab,Extension,No,Boehringer Ingelheim International GmbH,13/10/2022,nan,Immuo-mod,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Tecentriq,atezolizumab,Extension,Yes,Roche Registration GmbH,19/07/2017,04/07/2024,Cancer,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,D11,Anzupgo,delgocitinib,Initial approval,No,LEO Pharma A/S,25/07/2024,nan,Dermatology,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,A05,Iqirvo,elafibranor,Initial approval,No,Ipsen Pharma,25/07/2024,nan,Alimentary,Yes,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,A05,Kayfanda,odevixibat,Initial approval,No,Ipsen Pharma,25/07/2024,nan,Alimentary,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Loqtorzi,toripalimab,Initial approval,Yes,TMC Pharma (EU) Limited,25/07/2024,nan,Cancer,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,S01,Vevizye,ciclosporin,Initial approval,No,Novaliq GmbH,25/07/2024,nan,Sense organs,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Vyloy,zolbetuximab,Initial approval,Yes,Astellas Pharma Europe B.V.,25/07/2024,nan,Cancer,Yes,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,C02,Yuvanci,macitentan / tadalafil,Initial approval,No,Janssen-Cilag International NV,25/07/2024,nan,Cardiovascular,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,J07,Arexvy,"Respiratory syncytial virus, glycoprotein F, recombinant, stabilised in the pre-fusion conformation, adjuvanted with AS01E",Extension,No,GlaxoSmithkline Biologicals S.A.,nan,27/06/2024,Infectives,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Braftovi,encorafenib,Extension,Yes,Pierre Fabre Medicament,26/07/2018,19/03/2024,Cancer,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,J05,Edurant,rilpivirine,Extension,No,Janssen-Cilag International N.V.,nan,28/10/2022,Infectives,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Mektovi,binimetinib,Extension,Yes,Pierre Fabre Medicament,nan,17/06/2024,Cancer,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Keytruda,pembrolizumab,Extension,Yes,Merck Sharp & Dohme B.V.,20/05/2015,08/07/2024,Cancer,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,C02,Opsumit,macitentan,Extension,No,Janssen-Cilag International N.V.,nan,01/12/2022,Cardiovascular,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Padcev,enfortumab vedotin,Extension,Yes,Astellas Pharma Europe B.V.,24/02/2022,29/11/2023,Cancer,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Rybrevant,amivantamab,Extension,Yes,Janssen-Cilag International N.V.,14/10/2021,27/06/2024,Cancer,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,N05,Slenyto,melatonin,Extension,No,RAD Neurim Pharmaceuticals EEC SARL,26/07/2018,16/02/2024,CNS,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L04,Spevigo,spesolimab,Extension,No,Boehringer Ingelheim International GmbH,13/10/2022,nan,Immuo-mod,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Tecentriq,atezolizumab,Extension,Yes,Roche Registration GmbH,19/07/2017,04/07/2024,Cancer,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,D11,Anzupgo,delgocitinib,Initial approval,No,LEO Pharma A/S,25/07/2024,nan,Dermatology,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,A05,Iqirvo,elafibranor,Initial approval,No,Ipsen Pharma,25/07/2024,nan,Alimentary,Yes,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,A05,Kayfanda,odevixibat,Initial approval,No,Ipsen Pharma,25/07/2024,nan,Alimentary,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Loqtorzi,toripalimab,Initial approval,Yes,TMC Pharma (EU) Limited,25/07/2024,nan,Cancer,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,S01,Vevizye,ciclosporin,Initial approval,No,Novaliq GmbH,25/07/2024,nan,Sense organs,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Vyloy,zolbetuximab,Initial approval,Yes,Astellas Pharma Europe B.V.,25/07/2024,nan,Cancer,Yes,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,C02,Yuvanci,macitentan / tadalafil,Initial approval,No,Janssen-Cilag International NV,25/07/2024,nan,Cardiovascular,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,J07,Arexvy,"Respiratory syncytial virus, glycoprotein F, recombinant, stabilised in the pre-fusion conformation, adjuvanted with AS01E",Extension,No,GlaxoSmithkline Biologicals S.A.,nan,27/06/2024,Infectives,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Braftovi,encorafenib,Extension,Yes,Pierre Fabre Medicament,26/07/2018,19/03/2024,Cancer,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,J05,Edurant,rilpivirine,Extension,No,Janssen-Cilag International N.V.,nan,28/10/2022,Infectives,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Mektovi,binimetinib,Extension,Yes,Pierre Fabre Medicament,nan,17/06/2024,Cancer,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Keytruda,pembrolizumab,Extension,Yes,Merck Sharp & Dohme B.V.,20/05/2015,08/07/2024,Cancer,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,C02,Opsumit,macitentan,Extension,No,Janssen-Cilag International N.V.,nan,01/12/2022,Cardiovascular,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Padcev,enfortumab vedotin,Extension,Yes,Astellas Pharma Europe B.V.,24/02/2022,29/11/2023,Cancer,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Rybrevant,amivantamab,Extension,Yes,Janssen-Cilag International N.V.,14/10/2021,27/06/2024,Cancer,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,N05,Slenyto,melatonin,Extension,No,RAD Neurim Pharmaceuticals EEC SARL,26/07/2018,16/02/2024,CNS,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L04,Spevigo,spesolimab,Extension,No,Boehringer Ingelheim International GmbH,13/10/2022,nan,Immuo-mod,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Tecentriq,atezolizumab,Extension,Yes,Roche Registration GmbH,19/07/2017,04/07/2024,Cancer,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,D11,Anzupgo,delgocitinib,Initial approval,No,LEO Pharma A/S,25/07/2024,nan,Dermatology,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,A05,Iqirvo,elafibranor,Initial approval,No,Ipsen Pharma,25/07/2024,nan,Alimentary,Yes,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,A05,Kayfanda,odevixibat,Initial approval,No,Ipsen Pharma,25/07/2024,nan,Alimentary,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Loqtorzi,toripalimab,Initial approval,Yes,TMC Pharma (EU) Limited,25/07/2024,nan,Cancer,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,S01,Vevizye,ciclosporin,Initial approval,No,Novaliq GmbH,25/07/2024,nan,Sense organs,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Vyloy,zolbetuximab,Initial approval,Yes,Astellas Pharma Europe B.V.,25/07/2024,nan,Cancer,Yes,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,C02,Yuvanci,macitentan / tadalafil,Initial approval,No,Janssen-Cilag International NV,25/07/2024,nan,Cardiovascular,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,J07,Arexvy,"Respiratory syncytial virus, glycoprotein F, recombinant, stabilised in the pre-fusion conformation, adjuvanted with AS01E",Extension,No,GlaxoSmithkline Biologicals S.A.,nan,27/06/2024,Infectives,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Braftovi,encorafenib,Extension,Yes,Pierre Fabre Medicament,26/07/2018,19/03/2024,Cancer,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,J05,Edurant,rilpivirine,Extension,No,Janssen-Cilag International N.V.,nan,28/10/2022,Infectives,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Mektovi,binimetinib,Extension,Yes,Pierre Fabre Medicament,nan,17/06/2024,Cancer,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Keytruda,pembrolizumab,Extension,Yes,Merck Sharp & Dohme B.V.,20/05/2015,08/07/2024,Cancer,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,C02,Opsumit,macitentan,Extension,No,Janssen-Cilag International N.V.,nan,01/12/2022,Cardiovascular,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Padcev,enfortumab vedotin,Extension,Yes,Astellas Pharma Europe B.V.,24/02/2022,29/11/2023,Cancer,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Rybrevant,amivantamab,Extension,Yes,Janssen-Cilag International N.V.,14/10/2021,27/06/2024,Cancer,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,N05,Slenyto,melatonin,Extension,No,RAD Neurim Pharmaceuticals EEC SARL,26/07/2018,16/02/2024,CNS,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L04,Spevigo,spesolimab,Extension,No,Boehringer Ingelheim International GmbH,13/10/2022,nan,Immuo-mod,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Tecentriq,atezolizumab,Extension,Yes,Roche Registration GmbH,19/07/2017,04/07/2024,Cancer,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,D11,Anzupgo,delgocitinib,Initial approval,No,LEO Pharma A/S,25/07/2024,nan,Dermatology,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,A05,Iqirvo,elafibranor,Initial approval,No,Ipsen Pharma,25/07/2024,nan,Alimentary,Yes,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,A05,Kayfanda,odevixibat,Initial approval,No,Ipsen Pharma,25/07/2024,nan,Alimentary,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Loqtorzi,toripalimab,Initial approval,Yes,TMC Pharma (EU) Limited,25/07/2024,nan,Cancer,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,S01,Vevizye,ciclosporin,Initial approval,No,Novaliq GmbH,25/07/2024,nan,Sense organs,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Vyloy,zolbetuximab,Initial approval,Yes,Astellas Pharma Europe B.V.,25/07/2024,nan,Cancer,Yes,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,C02,Yuvanci,macitentan / tadalafil,Initial approval,No,Janssen-Cilag International NV,25/07/2024,nan,Cardiovascular,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,J07,Arexvy,"Respiratory syncytial virus, glycoprotein F, recombinant, stabilised in the pre-fusion conformation, adjuvanted with AS01E",Extension,No,GlaxoSmithkline Biologicals S.A.,nan,27/06/2024,Infectives,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Braftovi,encorafenib,Extension,Yes,Pierre Fabre Medicament,26/07/2018,19/03/2024,Cancer,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,J05,Edurant,rilpivirine,Extension,No,Janssen-Cilag International N.V.,nan,28/10/2022,Infectives,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Mektovi,binimetinib,Extension,Yes,Pierre Fabre Medicament,nan,17/06/2024,Cancer,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Keytruda,pembrolizumab,Extension,Yes,Merck Sharp & Dohme B.V.,20/05/2015,08/07/2024,Cancer,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,C02,Opsumit,macitentan,Extension,No,Janssen-Cilag International N.V.,nan,01/12/2022,Cardiovascular,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Padcev,enfortumab vedotin,Extension,Yes,Astellas Pharma Europe B.V.,24/02/2022,29/11/2023,Cancer,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Rybrevant,amivantamab,Extension,Yes,Janssen-Cilag International N.V.,14/10/2021,27/06/2024,Cancer,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,N05,Slenyto,melatonin,Extension,No,RAD Neurim Pharmaceuticals EEC SARL,26/07/2018,16/02/2024,CNS,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L04,Spevigo,spesolimab,Extension,No,Boehringer Ingelheim International GmbH,13/10/2022,nan,Immuo-mod,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Tecentriq,atezolizumab,Extension,Yes,Roche Registration GmbH,19/07/2017,04/07/2024,Cancer,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,D11,Anzupgo,delgocitinib,Initial approval,No,LEO Pharma A/S,25/07/2024,nan,Dermatology,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,A05,Iqirvo,elafibranor,Initial approval,No,Ipsen Pharma,25/07/2024,nan,Alimentary,Yes,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,A05,Kayfanda,odevixibat,Initial approval,No,Ipsen Pharma,25/07/2024,nan,Alimentary,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Loqtorzi,toripalimab,Initial approval,Yes,TMC Pharma (EU) Limited,25/07/2024,nan,Cancer,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,S01,Vevizye,ciclosporin,Initial approval,No,Novaliq GmbH,25/07/2024,nan,Sense organs,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Vyloy,zolbetuximab,Initial approval,Yes,Astellas Pharma Europe B.V.,25/07/2024,nan,Cancer,Yes,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,C02,Yuvanci,macitentan / tadalafil,Initial approval,No,Janssen-Cilag International NV,25/07/2024,nan,Cardiovascular,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,J07,Arexvy,"Respiratory syncytial virus, glycoprotein F, recombinant, stabilised in the pre-fusion conformation, adjuvanted with AS01E",Extension,No,GlaxoSmithkline Biologicals S.A.,nan,27/06/2024,Infectives,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Braftovi,encorafenib,Extension,Yes,Pierre Fabre Medicament,26/07/2018,19/03/2024,Cancer,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,J05,Edurant,rilpivirine,Extension,No,Janssen-Cilag International N.V.,nan,28/10/2022,Infectives,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Mektovi,binimetinib,Extension,Yes,Pierre Fabre Medicament,nan,17/06/2024,Cancer,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Keytruda,pembrolizumab,Extension,Yes,Merck Sharp & Dohme B.V.,20/05/2015,08/07/2024,Cancer,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,C02,Opsumit,macitentan,Extension,No,Janssen-Cilag International N.V.,nan,01/12/2022,Cardiovascular,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Padcev,enfortumab vedotin,Extension,Yes,Astellas Pharma Europe B.V.,24/02/2022,29/11/2023,Cancer,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Rybrevant,amivantamab,Extension,Yes,Janssen-Cilag International N.V.,14/10/2021,27/06/2024,Cancer,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,N05,Slenyto,melatonin,Extension,No,RAD Neurim Pharmaceuticals EEC SARL,26/07/2018,16/02/2024,CNS,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L04,Spevigo,spesolimab,Extension,No,Boehringer Ingelheim International GmbH,13/10/2022,nan,Immuo-mod,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Tecentriq,atezolizumab,Extension,Yes,Roche Registration GmbH,19/07/2017,04/07/2024,Cancer,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,D11,Anzupgo,delgocitinib,Initial approval,No,LEO Pharma A/S,25/07/2024,nan,Dermatology,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,A05,Iqirvo,elafibranor,Initial approval,No,Ipsen Pharma,25/07/2024,nan,Alimentary,Yes,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,A05,Kayfanda,odevixibat,Initial approval,No,Ipsen Pharma,25/07/2024,nan,Alimentary,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Loqtorzi,toripalimab,Initial approval,Yes,TMC Pharma (EU) Limited,25/07/2024,nan,Cancer,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,S01,Vevizye,ciclosporin,Initial approval,No,Novaliq GmbH,25/07/2024,nan,Sense organs,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Vyloy,zolbetuximab,Initial approval,Yes,Astellas Pharma Europe B.V.,25/07/2024,nan,Cancer,Yes,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,C02,Yuvanci,macitentan / tadalafil,Initial approval,No,Janssen-Cilag International NV,25/07/2024,nan,Cardiovascular,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,J07,Arexvy,"Respiratory syncytial virus, glycoprotein F, recombinant, stabilised in the pre-fusion conformation, adjuvanted with AS01E",Extension,No,GlaxoSmithkline Biologicals S.A.,nan,27/06/2024,Infectives,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Braftovi,encorafenib,Extension,Yes,Pierre Fabre Medicament,26/07/2018,19/03/2024,Cancer,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,J05,Edurant,rilpivirine,Extension,No,Janssen-Cilag International N.V.,nan,28/10/2022,Infectives,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Mektovi,binimetinib,Extension,Yes,Pierre Fabre Medicament,nan,17/06/2024,Cancer,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Keytruda,pembrolizumab,Extension,Yes,Merck Sharp & Dohme B.V.,20/05/2015,08/07/2024,Cancer,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,C02,Opsumit,macitentan,Extension,No,Janssen-Cilag International N.V.,nan,01/12/2022,Cardiovascular,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Padcev,enfortumab vedotin,Extension,Yes,Astellas Pharma Europe B.V.,24/02/2022,29/11/2023,Cancer,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Rybrevant,amivantamab,Extension,Yes,Janssen-Cilag International N.V.,14/10/2021,27/06/2024,Cancer,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,N05,Slenyto,melatonin,Extension,No,RAD Neurim Pharmaceuticals EEC SARL,26/07/2018,16/02/2024,CNS,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L04,Spevigo,spesolimab,Extension,No,Boehringer Ingelheim International GmbH,13/10/2022,nan,Immuo-mod,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Tecentriq,atezolizumab,Extension,Yes,Roche Registration GmbH,19/07/2017,04/07/2024,Cancer,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,D11,Anzupgo,delgocitinib,Initial approval,No,LEO Pharma A/S,25/07/2024,nan,Dermatology,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,A05,Iqirvo,elafibranor,Initial approval,No,Ipsen Pharma,25/07/2024,nan,Alimentary,Yes,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,A05,Kayfanda,odevixibat,Initial approval,No,Ipsen Pharma,25/07/2024,nan,Alimentary,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Loqtorzi,toripalimab,Initial approval,Yes,TMC Pharma (EU) Limited,25/07/2024,nan,Cancer,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,S01,Vevizye,ciclosporin,Initial approval,No,Novaliq GmbH,25/07/2024,nan,Sense organs,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Vyloy,zolbetuximab,Initial approval,Yes,Astellas Pharma Europe B.V.,25/07/2024,nan,Cancer,Yes,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,C02,Yuvanci,macitentan / tadalafil,Initial approval,No,Janssen-Cilag International NV,25/07/2024,nan,Cardiovascular,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,J07,Arexvy,"Respiratory syncytial virus, glycoprotein F, recombinant, stabilised in the pre-fusion conformation, adjuvanted with AS01E",Extension,No,GlaxoSmithkline Biologicals S.A.,nan,27/06/2024,Infectives,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Braftovi,encorafenib,Extension,Yes,Pierre Fabre Medicament,26/07/2018,19/03/2024,Cancer,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,J05,Edurant,rilpivirine,Extension,No,Janssen-Cilag International N.V.,nan,28/10/2022,Infectives,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Mektovi,binimetinib,Extension,Yes,Pierre Fabre Medicament,nan,17/06/2024,Cancer,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Keytruda,pembrolizumab,Extension,Yes,Merck Sharp & Dohme B.V.,20/05/2015,08/07/2024,Cancer,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,C02,Opsumit,macitentan,Extension,No,Janssen-Cilag International N.V.,nan,01/12/2022,Cardiovascular,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Padcev,enfortumab vedotin,Extension,Yes,Astellas Pharma Europe B.V.,24/02/2022,29/11/2023,Cancer,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Rybrevant,amivantamab,Extension,Yes,Janssen-Cilag International N.V.,14/10/2021,27/06/2024,Cancer,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,N05,Slenyto,melatonin,Extension,No,RAD Neurim Pharmaceuticals EEC SARL,26/07/2018,16/02/2024,CNS,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L04,Spevigo,spesolimab,Extension,No,Boehringer Ingelheim International GmbH,13/10/2022,nan,Immuo-mod,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Tecentriq,atezolizumab,Extension,Yes,Roche Registration GmbH,19/07/2017,04/07/2024,Cancer,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,D11,Anzupgo,delgocitinib,Initial approval,No,LEO Pharma A/S,25/07/2024,nan,Dermatology,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,A05,Iqirvo,elafibranor,Initial approval,No,Ipsen Pharma,25/07/2024,nan,Alimentary,Yes,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,A05,Kayfanda,odevixibat,Initial approval,No,Ipsen Pharma,25/07/2024,nan,Alimentary,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Loqtorzi,toripalimab,Initial approval,Yes,TMC Pharma (EU) Limited,25/07/2024,nan,Cancer,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,S01,Vevizye,ciclosporin,Initial approval,No,Novaliq GmbH,25/07/2024,nan,Sense organs,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Vyloy,zolbetuximab,Initial approval,Yes,Astellas Pharma Europe B.V.,25/07/2024,nan,Cancer,Yes,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,C02,Yuvanci,macitentan / tadalafil,Initial approval,No,Janssen-Cilag International NV,25/07/2024,nan,Cardiovascular,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,J07,Arexvy,"Respiratory syncytial virus, glycoprotein F, recombinant, stabilised in the pre-fusion conformation, adjuvanted with AS01E",Extension,No,GlaxoSmithkline Biologicals S.A.,nan,27/06/2024,Infectives,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Braftovi,encorafenib,Extension,Yes,Pierre Fabre Medicament,26/07/2018,19/03/2024,Cancer,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,J05,Edurant,rilpivirine,Extension,No,Janssen-Cilag International N.V.,nan,28/10/2022,Infectives,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Mektovi,binimetinib,Extension,Yes,Pierre Fabre Medicament,nan,17/06/2024,Cancer,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Keytruda,pembrolizumab,Extension,Yes,Merck Sharp & Dohme B.V.,20/05/2015,08/07/2024,Cancer,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,C02,Opsumit,macitentan,Extension,No,Janssen-Cilag International N.V.,nan,01/12/2022,Cardiovascular,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Padcev,enfortumab vedotin,Extension,Yes,Astellas Pharma Europe B.V.,24/02/2022,29/11/2023,Cancer,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Rybrevant,amivantamab,Extension,Yes,Janssen-Cilag International N.V.,14/10/2021,27/06/2024,Cancer,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,N05,Slenyto,melatonin,Extension,No,RAD Neurim Pharmaceuticals EEC SARL,26/07/2018,16/02/2024,CNS,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L04,Spevigo,spesolimab,Extension,No,Boehringer Ingelheim International GmbH,13/10/2022,nan,Immuo-mod,No,Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024,26 July 2024,https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024,L01,Tecentriq,atezolizumab,Extension,Yes,Roche Registration GmbH,19/07/2017,04/07/2024,Cancer,No,Positive
